



Published in final edited form as:

Vitam Horm. 2007 ; 76: 203–261. doi:10.1016/S0083-6729(07)76008-9.

Tocotrienols: The Emerging Face of Natural Vitamin E

Chandan K. Sen, Savita Khanna, Cameron Rink, and Sashwati Roy

Laboratory of Molecular Medicine, Department of Surgery, Davis Heart & Lung Research Institute, The Ohio State University Medical Center, Columbus, Ohio 43210

Abstract

Natural vitamin E includes eight chemically distinct molecules: α -, β -, γ - and δ -tocopherol; and α -, β -, γ - and δ -tocotrienol. In the current literature, more than 95% of all studies on vitamin E are directed towards the specific study of α -tocopherol. The other forms of natural vitamin E remain poorly understood. The abundance of α -tocopherol in the human body and the comparable efficiency of all vitamin E molecules as antioxidants, led biologists to neglect the non-tocopherol vitamin E molecules as topics for basic and clinical research. Recent developments warrant a serious reconsideration of this conventional wisdom. The tocotrienol subfamily of natural vitamin E possesses powerful neuroprotective, anti-cancer and cholesterol lowering properties that are often not exhibited by tocopherols. Current developments in vitamin E research clearly indicate that members of the vitamin E family are not redundant with respect to their biological functions. α -Tocotrienol, γ -tocopherol, and δ -tocotrienol have emerged as vitamin E molecules with functions in health and disease that are clearly distinct from that of α -tocopherol. At nanomolar concentration, α -tocotrienol, not α -tocopherol, prevents neurodegeneration. On a concentration basis, this finding represents the most potent of all biological functions exhibited by any natural vitamin E molecule. Recently it has been suggested that the safe dose of various tocotrienols for human consumption is 200-1000 mg/d. A rapidly expanding body of evidence support that members of the vitamin E family are functionally unique. In recognition of this fact, title claims in manuscripts should be limited to the specific form of vitamin E studied. For example, evidence for toxicity of a specific form of tocopherol in excess may not be used to conclude that high-dosage “vitamin E” supplementation may increase all-cause mortality. Such conclusion incorrectly implies that tocotrienols are toxic as well under conditions where tocotrienols were not even considered. The current state of knowledge warrants strategic investment into the lesser known forms of vitamin E. This will enable prudent selection of the appropriate vitamin E molecule for studies addressing a specific health need.

I. Historical Developments and the Vitamin E Family

That certain foods are vital to maintaining healthy life was recognized long before the first vitamins were actually identified. In ancient times, the famous Greek physician Hippocrates not only described night blindness, a disease now known to be caused by a vitamin A deficiency, but recommended the eating of “ox liver dipped in honey” as a cure. In the centuries that followed, observers continued to report that certain diseases appeared to be nutritionally related. By and large, they attributed the problem to some unknown “toxic substance” in various foodstuffs. In 1747 when the Scottish physician James Lind proved he could cure scurvy by feeding citrus fruits to stricken sailors, his fellow physicians continued to ignore his work and to search for the “toxin” responsible for the illness. The unknown “toxins” were never found. In the last quarter of the nineteenth century, scientific thinking began to change. In 1886, Christiaan Eijkman, a physician working in the Dutch East Indies, began a serious investigation

into beriberi, a thiamine deficiency disease. Eijkman's studies indicated that beriberi in animals was caused by diets excessively high in polished rice and that it could be cured by substituting unpolished rice. In 1901, a younger colleague, Gerrit Grijns, determined that polished rice lacked an essential "anti-beriberi" substance that could be found in rice hulls and a number of other foods. Contemporary Englishman William Fletcher determined that if special factors (vitamins) were removed from food disease ensued. Fletcher was researching the causes of the disease beriberi when he discovered that eating unpolished rice prevented *Beriberi* and eating polished rice did not. William Fletcher believed that there were special nutrients contained in the husk of the rice. Next year, English biochemist Sir Frederick Gowland Hopkins also discovered that certain "accessory food factors" were important to health. In 1912, Polish scientist Cashmir Funk named the special nutritional parts of food as a "vitamine" after "vita" meaning life and "amine" from compounds found in the thiamine he isolated from rice husks. Vitamine was later shortened to vitamin when it was discovered that not all of the vitamins contain nitrogen, and, therefore, not all are amines. Together, Hopkins and Funk formulated the vitamin hypothesis of deficiency disease - that a lack of vitamins could make people sick. At this point of time, the notion of fat-soluble vitamins was yet to be conceived.

Fat-soluble vitamins have their root in the 1913 discovery by Elmer V. McCollum, Thomas B. Osborne and Lafayette B. Mendel who isolated a growth-producing substance from egg yolks. The *substance* appeared quite different from the water-soluble vitamins already discovered. In 1916, McCollum went on to show that at least two factors were responsible for the normal growth of rats, factors he named fat-soluble A and water-soluble B. McCollum therefore is credited with initiating the custom of labeling vitamins by letters. Vitamin E was discovered in 1922 in green leafy vegetables by University of California researchers, Herbert Evans and Katherine Bishop (Evans and Bishop 1922). In 1924, Sure named it vitamin E. Because E supported fertility, it was scientifically named tocopherol. This comes from the Greek word *tokos* meaning childbirth, and *phero* meaning to bring forth, and the *ol* ending was added to indicate the alcohol properties of this molecule. In 1936 it was discovered that vitamin E was abundant in wheat germ oil. Two years later, it was chemically synthesized for the first time. The U.S. National Research Council sponsored studies on deficiencies of vitamin E, and based on the results E was designated an essential vitamin. Vitamin E emerged as an essential, fat-soluble nutrient that functions as an antioxidant in the human body. It is essential, because it is required to sustain life and the body cannot manufacture its own vitamin E and foods and supplements must provide it. Since the elucidation of the chemical structure of vitamin E in 1938 by Fenholtz and the synthesis of *dl*- α -tocopherol by Karrer in the same year, specific focus was directed on the chemical class of natural compounds that qualify to be vitamin E. Vitamin E was rediscovered as factor 2 antioxidant in 1965 (Schwarz 1965). α -Tocopherol drew most attention as the first natural form of vitamin E identified while its sisters remained under veil. At present, vitamin E represents a generic term for four tocopherols and four tocotrienols (Bruno and Traber 2006). In nature, eight substances have been found to have vitamin E activity: α -, β -, γ - and δ -tocopherol; and α -, β -, γ - and δ -tocotrienol. Although it has been claimed that tocotrienol may be metabolized to tocopherol in the human tissue (Qureshi *et al.*, 2001c; Qureshi *et al.*, 2002), the concept has not gained wide acceptance and the hypothesis remains open for additional considerations.

II. Biosynthesis of Tocopherols and Tocotrienols

Tocopherols consist of a chromanol ring and a 15-carbon tail derived from homogentisate (HGA) and phytol diphosphate, respectively (Fig. 1). Condensation of HGA and phytol diphosphate, the committed step in tocopherol biosynthesis, is catalyzed by HGA phytoltransferase (HPT)(Venkatesh *et al.*, 2006). Tocopherol helps maintain optimal photosynthesis rate under high-light stress (Porfirova *et al.*, 2002). Tocotrienols differ structurally from tocopherols by the presence of three *trans* double bonds in the hydrocarbon

tail. Because of these unsaturations in the isoprenoid side-chain, tocotrienols are thought to assume a unique conformation (Atkinson 2006). α -Tocotrienol seems to be very likely much more flexible in the sidechain and that it puts a greater curvature stress on phospholipid membranes. This has been confirmed in scanning calorimetry data (unpublished personal communication by Dr. Jeffrey Atkinson).

Tocotrienols are the primary form of vitamin E in the seed endosperm of most monocots, including agronomically important cereal grains such as wheat, rice, and barley. Palm oil contains significant quantities of tocotrienol (Sundram *et al.*, 2003). Tocotrienols are also found in the seed endosperm of a limited number of dicots, including *Apiaceae* species and certain *Solanaeaceae* species, such as tobacco. These molecules are found only rarely in vegetative tissues of plants. Crude palm oil extracted from the fruits of *Elaeis guineensis* particularly contains a high amount of tocotrienols (up to 800 mg/kg), mainly consisting of γ -tocotrienol and α -tocotrienol. Compared to tocopherols, tocotrienols are considerably less widespread in the plant kingdom (Horvath *et al.*, 2006). In 80 different plant species studied, twenty-four were found to contain significant amounts of tocotrienols. No taxonomic relation was apparent among the 16 dicotyledonous species that were found to contain tocotrienol.

Monocotyledonous species (eight species) belonged either to the *Poaceae* (six species) or the *Aracaceae* (two species). A more detailed analysis of tocotrienol accumulation revealed the presence of this natural vitamin E in several non-photosynthetic tissues and organs, *i.e.* seeds, fruits and in latex. No tocotrienols could be detected in mature photosynthetic tissues. Transient accumulation of low levels of tocotrienols is found in the young coleoptiles of plant species whose seeds contained tocotrienols. No measurable tocotrienol biosynthesis was apparent in coleoptiles, or in chloroplasts isolated from such coleoptiles. Tocotrienol accumulation in coleoptiles was not associated with chloroplasts. Tocotrienols seem to be transiently present in photosynthetically active tissues, however, it remains to be proven whether they are biosynthesized in such tissues, or imported from elsewhere in the plant (Horvath *et al.*, 2006).

In contrast to tocotrienols, tocopherols occur ubiquitously in plant tissues and are the exclusive form of vitamin E in leaves of plants and seeds of most dicots. Transgenic expression of the barley HGGT (homogentisic acid transferase, which catalyzes the committed step of tocotrienol biosynthesis) in *Arabidopsis thaliana* leaves resulted in accumulation of tocotrienols, which were absent from leaves of non-transformed plants, and a 10- to 15-fold increase in total vitamin E antioxidants (tocotrienols plus tocopherols). Overexpression of the barley HGGT in corn seeds resulted in an increase in tocotrienol and tocopherol content of as much as six-fold. These results provide insight into the genetic basis for tocotrienol biosynthesis in plants and demonstrate the ability to enhance the antioxidant content of crops by introduction of an enzyme that redirects metabolic flux (Cahoon *et al.*, 2003). More recently, another strategy involving genetic engineering of metabolic pathways in plants has proved to be efficient in bolstering tocotrienol biosynthesis (Rippert *et al.*, 2004). In plants, phenylalanine is the precursor of a myriad of secondary compounds termed phenylpropanoids. In contrast, much less carbon is incorporated into tyrosine that provides p-hydroxyphenylpyruvate and homogentisate, the aromatic precursors of vitamin E. The flux of these two compounds has been upregulated by deriving their synthesis directly at the level of prephenate. This was achieved by the expression of the yeast prephenate dehydrogenase gene in tobacco plants that already over-express the *Arabidopsis* p-hydroxyphenylpyruvate dioxygenase coding sequence. Massive accumulation of tocotrienols was observed in leaves. These molecules, which were undetectable in wild-type leaves, became the major forms of vitamin E in the leaves of the transgenic lines. An increased resistance of the transgenic plants toward the herbicidal p-hydroxyphenylpyruvate dioxygenase inhibitor diketonitril was also observed. Thus, the synthesis of p-hydroxyphenylpyruvate is a limiting step for the accumulation of vitamin E in plants (Rippert *et al.*, 2004).

III. Changing Trends in Vitamin E Research

A striking asymmetry in our understanding of the eight-member natural vitamin E tocol family has deprived us of the full complement of benefits offered by the natural vitamin E molecules (Fig. 2). Approximately only 1% of the entire literature on vitamin E addresses tocotrienols. A review of the NIH CRISP database shows that funding for tocotrienol research represents less than 1% of all vitamin E research during the last 30+ years. Within the tocopherol literature, the non- α forms remain poorly studied (Dietrich *et al.*, 2006; Hensley *et al.*, 2004; O'Byrne *et al.*, 2000). This represents a major void in vitamin E research. It is important that conclusions drawn about the usefulness of vitamin E as a whole to human health be drawn in this light. At present, conclusions drawn about vitamin E as whole in light of results from α -tocopherol studies alone (Friedrich 2004; Gorman 2005; Greenberg 2005; Hathcock *et al.*, 2005; Miller *et al.*, 2005) can be misleading. It is important to recognize the gaping voids in our understanding of the non- α -tocopherol forms of vitamin E and develop a more symmetrical understanding which would enable us to pick the right form of vitamin E for specific health indications. In this context we need to be cognizant of the fact the biological functions of the different homologues of natural vitamin E are not identical. Evidence supporting the unique biological significance of vitamin E family members is provided by current results derived from α -tocotrienol research. During the last 5 years, tocotrienol research has gained substantial momentum (Fig. 2). More than two-thirds (189/280) of the entire PubMed literature on tocotrienols has been published on or after 2000. This represents a major swing in the direction of vitamin E research.

IV. Unique Biological Functions of Tocotrienols

All eight tocols in the vitamin E family share close structural similarity (Fig. 1) and hence comparable antioxidant efficacy. Yet, current studies of the biological functions of vitamin E continue to indicate that members of the vitamin E family possess unique biological functions often not shared by other family members. One of the earliest observations suggesting that α -tocopherol may have functions independent of its antioxidant property came from the study of platelet adhesion. α -Tocopherol strongly inhibits platelet adhesion. Doses of 400 IU/day provide greater than 75% inhibition of platelet adhesion to a variety of adhesive proteins when tested at low shear rate in a laminar flow chamber. The antiadhesive effect of α -tocopherol appears to be related to a reduction in the number and size of pseudopodia upon platelet activation and this finding led to the hypothesis that within the body vitamin E may exert functions beyond its antioxidant property (Steiner 1993). That members of the tocopherol family may have functions independent of their antioxidant properties gained more prominence when vitamin E molecules with comparable antioxidant properties exhibited contrasting biological effects (Boscoboinik *et al.*, 1991). At the post-translational level, α -tocopherol inhibits protein kinase C, 5-lipoxygenase and phospholipase A2 and activates protein phosphatase 2A and diacylglycerol kinase. Some genes (*e.g.* scavenger receptors, α -TTP, α -tropomyosin, matrix metalloproteinase-19 and collagenase) are specifically modulated by α -tocopherol at the transcriptional level. α -Tocopherol also inhibits cell proliferation, platelet aggregation and monocyte adhesion. These effects have been characterized to be unrelated to the antioxidant activity of vitamin E, and possibly reflect specific interactions of α -tocopherol with enzymes, structural proteins, lipids and transcription factors (Zingg and Azzi 2004). γ -Tocopherol represents the major form of vitamin E in the diet in the USA, but not in Europe. Desmethyl tocopherols, such as γ -tocopherol and specific tocopherol metabolites, most notably the carboxyethyl-hydroxychroman (CEHC) products, exhibit functions that are not shared by α -tocopherol. The activities of these other tocopherols do not map directly to their chemical antioxidant behavior but rather reflect anti-inflammatory, antineoplastic, and natriuretic functions possibly mediated through specific binding interactions (Hensley *et al.*,

2004). Metabolites of γ -tocopherol (2,7,8-trimethyl-2-(β -carboxyethyl)-6-hydroxychroman), but not that of α -tocopherol, provides natriuretic activity. Moreover, a nascent body of epidemiological data suggests that γ -tocopherol is a better negative risk factor for certain types of cancer and myocardial infarction than is α -tocopherol (Wagner *et al.*, 2004).

α -Tocotrienol possesses numerous functions that are not shared by α -tocopherol (Sen *et al.*, 2006). For example, nanomolar concentrations of α -tocotrienol uniquely prevent inducible neurodegeneration by regulating specific mediators of cell death (Khanna *et al.*, 2006; Khanna *et al.*, 2003; Sen *et al.*, 2000). Oral supplementation of tocotrienol protects against stroke (Khanna *et al.*, 2005b). Micromolar amounts of tocotrienol suppress the activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the hepatic enzyme responsible for cholesterol synthesis (Pearce *et al.*, 1994; Pearce *et al.*, 1992). Tocopherols do not share the cholesterol-lowering properties of tocotrienol (Qureshi *et al.*, 1986; Qureshi *et al.*, 2002). Sterol-regulated ubiquitination marks HMG-CoA reductase for endoplasmic reticulum (ER)-associated degradation by 26S proteasomes. This degradation, which results from sterol-induced binding of reductase to ER membrane proteins called Insigs, contributes to the complex, multivalent feedback regulation of the enzyme. Recently it has been demonstrated that δ -tocotrienol stimulates ubiquitination and degradation of reductase and blocks processing of sterol regulatory element-binding proteins (SREBPs), another sterol-mediated action of Insigs. The γ -tocotrienol analog is more selective in enhancing reductase ubiquitination and degradation than blocking SREBP processing. Other forms of vitamin E neither accelerate reductase degradation nor block SREBP processing (Song and Debose-Boyd 2006).

Tocotrienol, not tocopherol, administration reduces oxidative protein damage and extends the mean life span of *C. elegans* (Adachi and Ishii 2000). Tocotrienols are thought to have more potent antioxidant properties than α -tocopherol (Serbinova *et al.*, 1991; Serbinova and Packer 1994). The unsaturated side chain of tocotrienol allows for more efficient penetration into tissues that have saturated fatty layers such as the brain and liver (Suzuki *et al.*, 1993). Experimental research examining the antioxidant, free radical scavenging effects of tocopherol and tocotrienols revealed that tocotrienols appear superior due to their better distribution in the fatty layers of the cell membrane (Suzuki *et al.*, 1993). Furthermore, tocotrienol but not tocopherol, suppresses growth of human breast cancer cells (Nesaretnam *et al.*, 1995).

In humans, tocotrienol supplementation results in peak blood plasma level of α -tocotrienol that is over an order of magnitude higher than that required to protect neurons against a range of neurotoxic insults (Khanna *et al.*, 2005a; Khanna *et al.*, 2006; Khanna *et al.*, 2003; Khanna *et al.*, 2005b; Khosla *et al.*, 2006; Sen *et al.*, 2000). Despite such promising potential, tocotrienol research accounts for roughly 1% of all vitamin E research published in PubMed. The unique vitamin action of α -tocopherol, combined with its prevalence in the human body and the similar efficiency of tocopherols as chain-breaking antioxidants, led biologists to almost completely discount the “minor” vitamin E molecules as topics for basic and clinical research. Recent discoveries warrant a serious reconsideration of this conventional wisdom.

V. Natural Sources of Tocotrienols

Tocotrienol is synthesized in edible as well as inedible plant products. Rubber latex represents a major non-food natural source of tocotrienols (Chow and Draper 1970; Horvath *et al.*, 2006; Whittle *et al.*, 1966). Identification of α -tocotrienol as a cholesterologenesis-inhibitory factor in barley (*Hordeum vulgare* L.) represents a landmark early discovery highlighting the unique significance of tocotrienols in health and disease (Qureshi *et al.*, 1986). Purification of an oily, non-polar fraction of high protein barley flour by high pressure liquid chromatography yielded 10 major components. Two of these components were identified as potent inhibitors

of cholesterologenesis both in vivo as well as in vitro. Addition of the purified inhibitor I (2.5-20 ppm) to chick diets significantly decreased hepatic cholesterologenesis and serum total and low density lipoprotein cholesterol and concomitantly increased lipogenic activity. The high resolution mass spectrometric analysis and measurement of different peaks of inhibitor I gave a molecular ion at m/e 424 (C₂₉H₄₄O₂) and main peaks at m/e 205, 203, and 165 corresponding to C₁₃H₁₇O₂, C₁₃H₁₅O₂, and C₁₀H₁₃O₂ moieties, respectively. Based on these results, d- α -tocotrienol was identified as the active principle. This identification was confirmed against synthetic samples (Qureshi *et al.*, 1986).

Palm oil represents one of the most abundant natural sources of tocotrienols (Elsom 1992). The distribution of vitamin E in palm oil is 30% tocopherols and 70% tocotrienols (Sundram *et al.*, 2003). The oil palm (*Elaeis guineensis*) is native to many West African countries, where local populations have used its oil for culinary and other purposes. Large-scale plantations, established principally in tropical regions of Asia, Africa and Latin America are mostly aimed at the production of oil (Solomons and Orozco 2003), which is extracted from the fleshy mesocarp of the palm fruit, and endosperm or kernel oil. Palm oil is different from other plant and animal oils in that it contains 50% saturated fatty acids, 40% unsaturated fatty acids, and 10% polyunsaturated fatty acids. Because of its high saturated fat content, palm oil has not been very popular in the United States. Hydrogenated fats contain high levels of trans-fatty acids which are now thought to have adverse health effects. The US Food and Drug Administration's final ruling on trans-fatty acid labeling issued in 2003 has caused a rapid transformation in the fat and oil industries (Tarrago-Trani *et al.*, 2006). Palm oil is free of trans-fatty acid and is rapidly gaining wider acceptance by the food industry in the country. Primary applications include bakery products, breakfast cereals, wafers and candies.

Rice bran oil, a by-product of the rice milling industry, is a major natural source of γ -tocotrienol but a poor source of α -tocotrienol. In addition, rice bran oil provides desmethyl tocotrienols. Two novel tocotrienols were isolated from stabilized and heated rice bran, apart from the known α -, β -, γ -, and δ -tocopherols and tocotrienols. These new tocotrienols are known as desmethyl tocotrienol [3, 4-dihydro-2-methyl-2-(4,8,12-trimethyltrideca-3'(E),7'(E), 11'-trienyl)-2H-1-benzopyran-6-ol] and didesmethyl tocotrienol [3, 4-dihydro-2-(4,8,12-trimethyltrideca-3'(E),7'(E), 11'-trienyl)-2H-1-benzopyran-6-ol] (Qureshi *et al.*, 2000). Although scientific evidence is relatively limited, rice bran oil (RBO) is tenaciously believed to be a healthy vegetable oil in Asian countries (Sugano *et al.*, 1999).

Cereals such as oat, rye and barley contain small amounts of tocotrienol in them. α -Tocotrienol is the predominant form of tocotrienol in oat (*Avena sativa L.*) and barley (56 and 40 mg/kg of dry weight, respectively). β -Tocotrienol is the major form of tocotrienol found in hulled and dehulled wheats (from 33 to 43 mg/kg of dry weight) (Panfili *et al.*, 2003). Steaming and flaking of dehulled oat groats results in moderate losses of tocotrienols but not of tocopherols (Bryngelsson *et al.*, 2002). Autoclaving of grains (including the hulls) increases the levels of all tocopherols and tocotrienols analyzed except β -tocotrienol, which was not affected. Drum drying of steamed rolled oats results in an almost complete loss of tocopherols and tocotrienols (Bryngelsson *et al.*, 2002). Although tocotrienols are present in edible natural products, it is questionable whether these dietary sources could provide sufficient amounts of tocotrienol to humans. Of note, processing of 1000 kg of crude palm oil is necessary to derive 1 kg of the commercial product Tocomin 50% (Carotech, NJ). Roughly, one would have to consume 100-200g of palm/rice-bran oil or 1.5-4 kg of wheat-germ, barley or oat to achieve doses that have been published to be effective biologically. With this consideration in mind, appropriately configured dietary supplements seem to be a prudent choice.

VI. BIOAVAILABILITY OF ORAL TOCOTRIENOLS

During the last two decades, efforts to understand how dietary vitamin E is transported to the tissues have focused on α -tocopherol transport (Blatt *et al.*, 2001; Kaempf-Rotzoll *et al.*, 2003; Traber and Arai 1999; Traber *et al.*, 2004). α -Tocopherol transfer protein (TTP) has been identified to mediate α -tocopherol secretion into the plasma while other tocopherol-binding proteins seem to play a less important role (Kaempf-Rotzoll *et al.*, 2003). Tocotrienols have been known for decades but why have they not been studied as well as α -tocopherol? Although there does not seem to be straightforward rational answer to this question, one contributing factor is whether tocotrienol taken orally reaches vital organs of the body. This concern was primarily based on a 1997 finding that the transport system, α -tocopherol transport protein (TTP), responsible to carry α -tocopherol to vital organs has a poorer efficiency to transport tocotrienols to tissues (Hosomi *et al.*, 1997). The lack of relative specific affinity of TTP for tocotrienols led to the notion that availability of dietary tocotrienol to vital organs is negligible.

TTP is a soluble 32-kDa protein expressed in liver that selectively binds and transports α -tocopherol. TTP maintains the concentration of serum α -tocopherol by facilitating α -tocopherol export from the liver. TTP is required to maintain normal α -tocopherol concentrations in plasma and extrahepatic tissues (Traber *et al.*, 2004). Although TTP is known to bind to α -tocotrienol with 8.5-fold lower affinity than that for α -tocopherol (Hosomi *et al.*, 1997), it has not been clear whether, or to what extent, the delivery of orally supplemented α -tocotrienol to vital organs is dependent on TTP. Previously it has been reported that TTP deficient females are infertile presumably because of vitamin E deficiency (Terasawa *et al.*, 2000). This important observation was confirmed in a lineage of TTP deficient mice. Placenta of pregnant TTP deficient females were severely impaired with marked reduction of labyrinthine trophoblasts, and the embryos died at mid-gestation even when fertilized eggs of TTP-containing wild-type mice were transferred into TTP-deficient recipients (Jishage *et al.*, 2001). Even in the presence of dietary α -tocopherol, TTP knock-out mice are known to suffer from α -tocopherol deficiency (Jishage *et al.*, 2001; Terasawa *et al.*, 2000). Recently it has been noted that oral supplementation of female mice with α -tocotrienol restored fertility of TTP knock-out mice suggesting that tocotrienol was successfully delivered to the relevant tissues and that tocotrienol supported reproductive function under conditions of α -tocopherol deficiency (Khanna *et al.*, 2005a). This observation was consistent with another line of evidence from rats where tocotrienol supplementation spared loss of fertility caused by long-term vitamin E deficiency in the diet (Khanna *et al.*, 2005a). TTP continues to be a key transport mechanism for the deliver of α -tocopherol to tissues. The significance of TTP in the transport of other forms of vitamin E remains unclear at present. It is clear, however, that natural isomers of vitamin E do get transported to vital organs even in the absence of TTP. Identification and characterization of TTP-independent vitamin E transport mechanisms *in vivo* is warranted.

Ten years ago in a study testing ligand specificity of vitamin E isomers for TTP concluded that the affinity of vitamin E analogs for TTP is one of the critical determinants of their biological activity (Hosomi *et al.*, 1997). This conclusion was based on the assumption that the biological function of vitamin E molecules is proportionate to their concentration and that vitamin E isomers have redundant function. Early postulates proposing that tissue concentration and relative biologic function of tocopherol and tocotrienol are disparate and possibly unrelated (Hayes *et al.*, 1993). Developments during the last decade taught us that both assumptions are incorrect warranting a revisit of the fundamental principles that guide vitamin E research (Azzi *et al.*, 1995; Azzi and Stocker 2000; Sen *et al.*, 2004; Sen *et al.*, 2006). Another contemporary study reported that tocotrienols, supplemented to laboratory chow, do not reach the brain (Podda *et al.*, 1996). Taken together, the case for *in vivo* efficacy of oral tocotrienol was

seriously weakened by these reports (Hosomi *et al.*, 1997; Podda *et al.*, 1996). Today, however, the scenario has strikingly changed in light of new knowledge. For example, it is now clear that oral tocotrienol not only reaches the brain (Khanna *et al.*, 2005a; Khanna *et al.*, 2005b; Roy *et al.*, 2002) but it does so in amounts sufficient to protect against stroke (Khanna *et al.*, 2005b). The standard laboratory chow contains excessive amounts of α -tocopherol (Khosla *et al.*, 2006; van der Worp *et al.*, 1998) but negligible amounts of tocotrienol. Long-term lack of tocotrienol in the diet may repress any putative tocotrienol transport mechanism *in vivo*. Thus, long-term supplementation studies are needed. In light of the knowledge that natural analogs of vitamin E may compete for specific transporting mechanisms (Hosomi *et al.*, 1997), it is important that tocotrienol supplementation be performed under conditions of minimized co-presence of tocopherols. Another related consideration is that although incorporation of orally supplemented vitamin E into tissues is a slow and progressive process, rapid incorporation of the supplement into tissues of newborns may occur in response to gavaging of pregnant mother rats (Roy *et al.*, 2002). Thus, an experimental design incorporating long-term tocotrienol supplementation under conditions of minimal dietary co-presence of tocopherols and breeding of the supplemented colony would be a valuable approach to generate proof of principle testing whether dietary α -tocotrienol is capable of being transported to vital organs *in vivo*. In a recent study rats were maintained on vitamin E deficient diet and gavaged with α -tocotrienol alone, α -tocopherol alone or in combination. Five generations of rats were studied over sixty weeks (Khanna *et al.*, 2005a). Skin, adipose, heart, lungs, skeletal muscle brain, spinal cord, liver and blood were studied. Oral tocotrienol was delivered to all vital organs. In some tissues, the level of tocotrienol exceeded that of tocopherols indicating the presence of an efficient tocotrienol transport system *in vivo*. Baseline levels of α -tocotrienol in the skin of tocopherol-fed rats that never received any tocotrienol supplementation were negligible. Orally supplemented tocotrienol was rapidly taken up by the skin. Already in second generation rats, α -tocotrienol levels in the skin of tocotrienol supplemented rats exceeded twice the α -tocopherol levels in that organ. Of note, the α -tocotrienol level in the skin matched the α -tocotrienol level in the skin of rats fed with a comparable amount of tocopherol. When tocotrienol and tocopherol were co-supplemented, the uptake of α -tocotrienol by the skin was clearly blunted. In this group, α -tocotrienol levels were lower than α -tocotrienol levels in the skin suggesting a direct competition between orally taken tocotrienol and tocopherol for delivery to the skin. Longer supplementation resulted in a marked increase in the α -tocotrienol levels in the skin of tocotrienol-fed rats indicating a build-up of α -tocotrienol over time. Interestingly, the levels of α -tocotrienol in the skin of these rats were folds higher than the α -tocopherol level in the skin of tocopherol-fed rats. This observation suggests the presence of an effective transport mechanism delivering α -tocotrienol to the skin and efficient retention of α -tocotrienol in the skin over time. Co-supplementation of tocotrienol and tocopherol demonstrated favorable uptake of α -tocopherol over α -tocotrienol. Adipose tissue serves as storage organ for vitamin E (Adachi *et al.*, 1990). Analysis of adipose tissue vitamin E content of fifth generation rats revealed substantially more accumulation of α -tocotrienol in that tissue than α -tocopherol.

In the case of tocotrienol as well as of tocopherol feeding, results from third and fifth generation rats indicate higher levels of vitamin E in the skin of female compared to that of male rats. This gender-specific effect suggesting better transport of tocotrienol in females than in males was noted as a general trend across all organs studied. Gender-based differences in the transport of dietary vitamins are known to exist in specific cases (Garry *et al.*, 1987). Although the effect of several physiological factors on vitamin E transport has been studied, the gender factor remains to be specifically addressed (Lodge *et al.*, 2004). Recently it has been demonstrated that γ -tocopherol is more rapidly metabolized in women than in men (Leonard *et al.*, 2005). The level of α -tocotrienol in the ovary was over five-fold higher than that in the testes from the corresponding males rats (Khanna *et al.*, 2005a). In the ovary, tocopherol is known to

accumulate via a lipoprotein receptor dependent mechanism (Aten *et al.*, 1994). Whether tocotrienol shares that mechanism remain to be tested.

Vitamin E enters the circulation from the intestine in chylomicrons. The conversion of chylomicrons to remnant particles results in the distribution of newly absorbed vitamin E to all of the circulating lipoproteins and ultimately to tissues. This enrichment of lipoproteins with vitamin E is a key mechanism by which vitamin E is delivered to tissues (Traber *et al.*, 2004). In the liver, newly absorbed dietary lipids are incorporated into nascent very low density lipoproteins. The liver is responsible for the control and release of α -tocopherol into blood plasma. In the absence of TTP, α -tocopherol is not secreted back into the plasma. Excess vitamin E is not accumulated in the liver, but is excreted, mostly in bile (Traber *et al.*, 2004). Recently it has been noted that α -tocotrienol levels in the liver of rats and of TTP-deficient mice was much lower than the levels of this vitamin E isoform in most peripheral tissues studied (Khanna *et al.*, 2005a). Such observation argues against a central role of the liver in delivering oral α -tocotrienol to peripheral tissues. TTP has the ability to bind to both α -tocopherol as well as α -tocotrienol. The affinity to bind α -tocopherol is several-fold higher than that for α -tocotrienol (Hosomi *et al.*, 1997). Thus, under conditions of co-existence, α -tocopherol is expected to out-compete α -tocotrienol for binding. Although studies with the TTP-deficient mice (Khanna *et al.*, 2005a) indicate the existence of a TTP-independent mechanisms for the tissue delivery of oral α -tocotrienol, observations in the rat (Khanna *et al.*, 2005a) indicate that the mechanisms for transporting α -tocopherol and α -tocotrienol seem to compete such that transport of α -tocopherol is favored. Thus, co-supplementation of α -tocopherol and α -tocotrienol is likely to compromise tissue delivery of α -tocotrienol (Khanna *et al.*, 2005a).

Few studies have specifically looked at the fate of oral tocotrienol supplementation in humans. In a study investigating the pharmacokinetics and bioavailability of α -, γ - and δ -tocotrienols under fed and fasted conditions in eight healthy volunteers, subjects were administered a single 300 mg oral dose of mixed tocotrienols under fed or fasted conditions. The peak concentration of α -tocotrienol in the blood plasma was just over $1\mu\text{M}$ (Yap *et al.*, 2001). The fed state increased the onset as well as the extent of absorption of tocotrienols by more than two folds. In addition, the mean apparent elimination half-life of α -, γ - and δ -tocotrienols was estimated to be 4.4, 4.3 and 2.3 h, respectively, being between 4.5- to 8.7-fold shorter than that reported for α -tocopherol (Yap *et al.*, 2001). In another study, human subjects took tocotrienyl acetate supplements (250 mg/d) for eight weeks while being on low-fat diet. In response to supplementation, the concentrations of tocotrienol in the mean blood plasma were as follows: α -tocotrienol, $0.98\mu\text{M}$; γ -tocotrienol, $0.54\mu\text{M}$; and δ -tocotrienol $0.09\mu\text{M}$ (O'Byrne *et al.*, 2000). Thus, tocotrienyl acetate supplements were observed to be hydrolyzed, absorbed, and detectable in human plasma. Recently, a novel formulation for improved absorption of tocotrienols has been developed (Ho *et al.*, 2003). Emulsions are known to increase absorption of fat-soluble drugs. This invention is based on SEDDS (self-emulsifying drug delivery systems) technology (Araya *et al.*, 2006; Gao and Morozowich 2006; Hong *et al.*, 2006). Soft-gelatin capsules (Tocovid Suprabio™) containing tocotrienol have been produced. Once ingested, the tocotrienols form emulsion when the contents are released and mixed with human gastrointestinal fluid. In a recent study using Tocovid Suprabio™ the post-absorptive fate of tocotrienol isomers and their association with lipoprotein subfractions was examined in humans (Khosla *et al.*, 2006). The peak α -tocotrienol concentrations in supplemented individuals averaged approximately $3\mu\text{M}$ in blood plasma, $1.7\mu\text{M}$ in LDL, $0.9\mu\text{M}$ in triglyceride-rich lipoprotein, and $0.5\mu\text{M}$ in HDL. This peak plasma concentration of α -tocotrienol is 2-3 times more than the peak concentration reported in previous studies using generic supplements not based on SEDDS (O'Byrne *et al.*, 2000; Yap *et al.*, 2001).

VII. BIOLOGICAL FUNCTIONS

The biological functions of tocotrienol known so far have been listed in Table 1. In this section, we discuss work that relate to the neuroprotective, anti-cancer and cholesterol-lowering activities of tocotrienol.

a. Neuroprotection

Glutamate-toxicity is a major contributor to neurodegeneration. It includes excitotoxicity and an oxidative stress component also known as oxytosis (Schubert and Piasecki 2001; Tan *et al.*, 2001). Murine HT hippocampal neuronal cells, lacking intrinsic excitotoxicity-pathway, have been used as a standard model to characterize the oxidant-dependent component of glutamate toxicity. In 1999, we conducted a side by side comparison of all eight forms of natural vitamin E in a model of glutamate-induced neurodegeneration of HT neural cells. In subsequent experiments it was observed that the neuroprotective property of tocotrienol applies not only to neural cell lines but also to primary cortical neurons. This line of experimentation led to an observation that eventually turned out to be the most potent function of any natural form of vitamin E on a concentration basis reported. Until then, all biological functions of vitamin E studied *in vitro* were observed at micromolar concentration. Our studies led to the first evidence that α -tocotrienol was the most potent neuroprotective form of vitamin E in glutamate-induced degeneration of HT4 hippocampal neurons (Sen *et al.*, 2000). What was striking in this study was the observation that nanomolar concentrations of α -tocotrienol, not α -tocopherol, provide complete neuroprotection. At such low dose, tocotrienol was not protective against direct oxidant insult suggesting that the observed neuroprotective effects of nanomolar tocotrienol was not dependent on the widely known antioxidant property of vitamin E. That tocotrienol-dependent neuroprotection includes a significant antioxidant-independent mechanism has been now established (Khanna *et al.*, 2006). The neuroprotective property of tocotrienol holds good not only in response to glutamate challenge but also in response to other insults such as homocysteic acid, glutathione deficiency, and linoleic acid induced oxidative stress (Khanna *et al.*, 2006; Sen *et al.*, 2000). It is now evident that at micromolar concentrations tocotrienol protects neural cells by virtue of its antioxidant property. At nanomolar concentrations, however, tocotrienol regulates specific neurodegenerative signaling processes.

The major tocotrienol-sensitive signaling pathways which are known to be involved in glutamate-induced neurodegeneration include c-Src and 12-lipoxygenase (Khanna *et al.*, 2006; Khanna *et al.*, 2003; Khanna *et al.*, 2005b; Sen *et al.*, 2004; Sen *et al.*, 2000). In our initial search for signaling pathways that are sensitive to tocotrienol and play a decisive role in neurodegeneration we were led to c-Src kinase (Sen *et al.*, 2000). c-Src and the structurally related members of the Src family are non-receptor tyrosine kinases that reside within the cell associated with cell membranes and appear to transduce signals from transmembrane receptors to the cell interior. SH2 and SH3 domains are known to play a central role in regulating the catalytic activity of src protein tyrosine kinase. High-resolution crystal structures of human Src, in their repressed state, have provided a structural explanation for how intramolecular interactions of the SH3 and SH2 domains stabilize the inactive conformation of Src (Thomas and Brugge 1997).

Our hypothesis that tocotrienol prevents neurodegeneration by regulating specific signaling processes involved in neurotoxicity led to screening for potential tocotrienol-sensitive candidate death pathways in HT4 cells. During such screening studies, inhibitors of the protein tyrosine kinase activity completely prevented glutamate-induced cell death. Herbimycin and geldanamycin potently inhibit c-Src tyrosine kinase activity (Hall *et al.*, 1994; Yoneda *et al.*, 1993) whereas lavendustin A is an inhibitor of extracellular growth factor receptor protein tyrosine kinase activity (Hsu *et al.*, 1991). The observation that herbimycin and geldanamycin,

but not lavendustin A prevented glutamate-induced death of HT4 neuronal cells hinted the involvement of c-Src kinase activity in the death pathway. Immunoprecipitation of tyrosine phosphorylated protein from cellular extracts confirmed that protein tyrosine phosphorylation reactions were indeed triggered by exposure of cells to elevated levels of glutamate, and that such reactions were inhibited by nanomolar concentrations of α -tocotrienol (Sen *et al.*, 2000). These results, however, did not provide any information regarding the specific kinases involved. The involvement of c-Src kinase activity in the death pathway was verified by experiments involving the over-expression of catalytically active or inactive src kinase. Indeed, over-expression of catalytically active Src-kinase markedly sensitized the cells to HT4 induced death. Tocotrienol treatment completely prevented glutamate-induced death even in active c-Src kinase over-expressing cells indicating that it either inhibited c-Src kinase activity or regulated one or more events upstream of c-Src kinase activation. Further evidence supporting this contention was provided by results obtained from the determination of c-Src kinase activity in HT4 cells. Glutamate treatment resulted in marked enhancement of c-Src kinase activity, and this change was completely blocked in cells treated with nanomolar amounts of α -tocotrienol. Further evidence establishing that signal transduction processes related to the cell death pathway are involved in glutamate-induced cytotoxicity was obtained from the study of ERK1 and ERK2 activation. Mitogen-activated/extracellular response kinase kinase (MEK) kinase (MEKK) is a serine-threonine kinase that regulates sequential protein phosphorylation pathways, leading to the activation of mitogen- activated protein kinases (MAPK), including members of the extracellular signal-regulated kinases (ERKs). MEKK selectively regulates signal transduction pathways that contribute to the apoptotic response (Johnson *et al.*, 1996). When activated, p44 and p42 MAPK (ERK1 and ERK2) are phosphorylated at specific threonine and tyrosine residues. ERK has been implicated in mediating the signaling events that precede apoptosis. ERK2 plays an active role in mediating anti-IgM-induced apoptosis of B cells (Lee and Koretzky 1998). It has been also shown that H₂O₂ induces the activation of multiple MAPKs in oligodendrocyte progenitors and that the activation of ERK is associated with oxidant- mediated cytotoxicity (Bhat and Zhang 1999). Our studies showed that ERK1 and 2 are sensitive to elevated levels of extracellular glutamate. Rapid activation of ERK, particularly ERK2, was observed in response to glutamate treatment. Such response of ERK was completely inhibited in cells treated with α -tocotrienol suggesting that α -tocotrienol influences an early event in the glutamate-induced death pathway (Sen *et al.*, 2000). In some cases Src kinase activity is known to be required for the activation of ERK (Aikawa *et al.*, 1997). Thus, it is likely tocotrienol inhibits inducible ERK activation by down-regulating Src kinase activity (Sen *et al.*, 2000).

c-Src is heavily expressed in the brain (Soriano *et al.*, 1991) and in human neural tissues (Pyper and Bolen 1989). Differentiating rodent neurons are known to express high levels of c-Src. In neurons and astrocytes, c-Src is present at 15-20 times higher levels than that found in fibroblasts. The specific activity of the c-Src protein from neuronal cultures is 6-12-times higher than that from the astrocyte cultures suggesting a key function of this protein in neurons (Brugge *et al.*, 1985). Initially, c-Src was identified as being important in growth cone-mediated neurite extension and synaptic plasticity (Maness *et al.*, 1988) and in neuronal differentiation (Ingraham *et al.*, 1989). Targeted disruption of c-Src, however, did not cause any abnormality in the brain (Soriano *et al.*, 1991). Our pursuit for the neuroprotective mechanisms of tocotrienols led to the first evidence demonstrating that rapid c-Src activation (Khanna *et al.*, 2002; Sen *et al.*, 2000) plays a central role in executing neurodegeneration. Consistently, it was demonstrated in a subsequent report that Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke (Paul *et al.*, 2001). Further support of our claim that c-Src is a key player in neurodegeneration is provided by observation that the Src family kinase-inhibitor PP2 reduces focal ischemic brain injury (Lennmyr *et al.*, 2004). Our observation that tocotrienol-dependent inhibition of c-Src is beneficial for neuroprotection has

now been extended to the heart. A recent study showed that c-Src mediates post-ischemic cardiac injury and dysfunction. Tocotrienol supplementation inhibited c-Src activation and protected the heart (Das *et al.*, 2005). Many intracellular pathways can be stimulated upon Src activation, and a variety of cellular consequences can result. High c-Src is tightly associated with carcinogenesis. c-Src inhibitors are being actively studied for cancer therapy (Alper and Bowden 2005; Ishizawa and Parsons 2004; Lau 2005; Shupnik 2004). Based on the inducible c-Src inhibitory properties of tocotrienol one may postulate that tocotrienol has anti-cancer properties. The anti-cancer properties of tocotrienol have been discussed in a separate section below.

GSH is the major cellular thiol present in mammalian cells and is critical for maintenance of redox homeostasis (Sun *et al.*, 2006). GSH is a key survival factor in cells of the nervous system and lowered [GSH]i is one of the early markers of neurotoxicity induced by a variety of agonists (Bains and Shaw 1997; Dringen *et al.*, 2000). We observed that α -tocotrienol clearly protects primary cortical neurons against a number of GSH-lowering neurotoxins (Khanna *et al.*, 2003). Of interest, the neurons survived even in the face of GSH loss. These observations led to the hypothesis that loss of [GSH]i alone is not lethal (Khanna *et al.*, 2003). Given that pro-GSH agents are known to be neuroprotective in a variety of scenarios (Bains and Shaw 1997; Han *et al.*, 1997; Schulz *et al.*, 2000) it becomes reasonable to hypothesize that glutamate-induced lowering of [GSH]i triggers downstream responses that execute cell death. Our works led to the identification of 12-lipoxygenase (12-Lox) as a key tocotrienol-sensitive mediator of neurodegeneration (Khanna *et al.*, 2003). Specific inhibition of 12-Lox by BL15 protected neurons from glutamate-induced degeneration although [GSH]i is compromised by 80%. Similar protective effects of BL15 were noted when BSO, a specific inhibitor of GSH synthesis, was used as the agonist. Importantly, neurons isolated from mice lacking the 12-lipoxygenase gene were observed to be resistant to glutamate-induced loss of viability (Khanna *et al.*, 2003). This key piece of evidence established that indeed 12-Lox represents a critical checkpoint in glutamate-induced neurodegeneration.

Understanding of the intracellular regulation of 12-lipoxygenase requires knowledge of the distribution of both enzyme protein and its activity. For example, in human erythroleukemia cells, the membrane fraction contains about 90% of the total cellular 12-Lox activity, whereas only 10% of 12-Lox activity resides in the cytosol. However, the majority of cellular 12-Lox protein is found in the cytosol (Hagmann *et al.*, 1993). Upon activation, 12-Lox may translocate to the membrane (Hagmann *et al.*, 1993). Consistently, we have observed the decreased presence of 12-Lox in the cytosol and increased presence in the membrane of glutamate-treated cells. For 5-lipoxygenase, both catalytic function and translocation of the enzyme from the cytosol to the membrane are known to be regulated by tyrosine kinases (Lepley *et al.*, 1996). Recently we have noted that 12-Lox is subject to rapid tyrosine phosphorylation in neuronal cells challenged with glutamate or GSH-lowering agents. Such rapid phosphorylation coincides with the timeline of c-Src activation (Khanna *et al.*, 2005b). Inhibitors of c-Src abrogated inducible 12-Lox tyrosine phosphorylation supporting the notion that c-Src may directly phosphorylate 12-Lox in challenged neurons. To test this hypothesis we utilized genetic approaches of over-expressing kinase-active, kinase-dead or dominant negative c-Src in neuronal cells. Findings from cell biology studies as well as from the study of c-Src and 12-Lox in cell-free systems indicate that in response to challenge by glutamate or GSH-lowering agents, c-Src is rapidly activated and phosphorylates 12-Lox. (Khanna *et al.*, 2005b).

Neurons and the brain are rich in arachidonic acid (AA; 20:4 ω -6). Massive amounts of AA are released from the membranes in response to brain ischemia or trauma (Bazan 1970; Bazan 1971a; Bazan 1971b; Bazan 1976; Bazan and Rakowski 1970). Subsequent work has established that AA and its metabolites may be neurotoxic. There are three major pathways of AA metabolism: lipoxygenases, cyclooxygenases, and cytochrome P450. The cyclooxygenase

pathway has been preliminarily ruled out from being a contributor to neurodegeneration (Kwon *et al.*, 2005). In the lipoxygenase pathway, metabolites of 12-Lox seem to be the major metabolite of arachidonic acid in the brain (Adesuyi *et al.*, 1985; Carlen *et al.*, 1994) as well as in cultured cortical neurons (Ishizaki and Murota 1991; Miyamoto *et al.*, 1987a; Miyamoto *et al.*, 1987b). Lipoxygenases, mainly 5-, 12- and 15-Lox, are named for their ability to insert molecular oxygen at the 5, 12, or 15-carbon atom of arachidonic acid forming a distinct hydroperoxy-eicosatetraenoic (HPETE) acid (Yamamoto 1992). 12-Lox produces 12(S)-HPETE which is further metabolized into four distinct products: an alcohol [12(S)-HETE], a ketone (12-keto-eicosatetraenoic acid), or two epoxy alcohols (hepoxilin A3 and B3). Immunohistochemical studies revealed the occurrence of 12-Lox in neurons; particularly in hippocampus, striatum, olivary nucleus, as well as in glial and in cerebral endothelial cells (Nishiyama *et al.*, 1992; Nishiyama *et al.*, 1993). Using immature cortical neurons and HT cells, it has been shown that a decrease in [GSH]i triggers the activation of neuronal 12-Lox, which leads to the production of peroxides, the influx of Ca²⁺, and ultimately to cell death (Li *et al.*, 1997; Tan *et al.*, 2001). The 12-Lox metabolite 12-HPETE proved to be capable of causing cell death (Gu *et al.*, 2001). Inhibition of 12-Lox protected cortical neurons from β -amyloid induced toxicity (Lebeau *et al.*, 2001). Intracellular calcium chelation delayed cell death by lipoxygenase-mediated free radicals in mouse cortical cultures (Wie *et al.*, 2001). In sum, 12-Lox poses clear threat to neuronal survival especially under GSH-deficient conditions.

Lipoxygenase activity is sensitive to vitamin E. α -Tocopherol strongly inhibits purified 5-Lox with a IC₅₀ of 5 μ M. The inhibition is independent of the antioxidant property of tocopherol. Tryptic digestion and peptide mapping of the 5-Lox-tocopherol complex indicated that tocopherol binds strongly to a single peptide (Reddanna *et al.*, 1985). Another study reported inhibition of 15-Lox by tocopherol *via* specific interaction with the enzyme protein (Grossman and Waksman 1984). Of interest, inhibitors specific for cyclooxygenase or 5-Lox are not effective in protecting neuronal cells against glutamate-induced death suggesting a specific role of 12-Lox in glutamate-induced death (Khanna *et al.*, 2003; Khanna *et al.*, 2005b). Our studies addressing the effect of α -tocotrienol on pure 12-Lox indicate that α -tocotrienol directly interacts with the enzyme to suppress arachidonic acid metabolism. *In silico* studies examining possible docking sites of α -tocotrienol to 12-Lox support the presence of a α -tocotrienol binding solvent cavity close to the active site. Previously it has been demonstrated in 15-Lox that COOH terminal of arachidonic acid enters this solvent cavity while accessing the catalytic site (Borngraber *et al.*, 1999). It is therefore plausible that the binding position of α -tocotrienol prevents access of the natural substrate arachidonic acid to the active site of 12-Lox (Khanna *et al.*, 2003). Does 12-Lox have a tangible impact on neurodegenerative processes *in vivo*? In 1992, it was reported that a mixed lipoxygenase/cyclooxygenase inhibitor SK&F 105809 reduced cerebral edema after closed head injury in rat (Shohami *et al.*, 1992). We noted that 12-Lox, but not 5-Lox (Kitagawa *et al.*, 2004), deficient mice were significantly protected against stroke-related injury of the brain (Khanna *et al.*, 2005b). The case for 12-Lox as an important mediator of neurodegeneration *in vivo* is gaining additional support from independent studies (Musiek *et al.*, 2006). 12-Lox has been also implicated in the pathogenesis of Alzheimer's (Yao *et al.*, 2005). α -Tocotrienol is capable of resisting neurodegeneration *in vivo* by opposing the c-Src and 12-Lox pathways.

b. Anticancer

Pure and mixed isoprenoids have potent anti-cancer activity (Mo and Elson 1999). As discussed earlier in this work, tocotrienols are isoprenoids but tocopherols are not. Unlike in the case of neuroprotection where α -tocotrienol has emerged to be the most potent isoform (Khanna *et al.*, 2006; Khanna *et al.*, 2005b; Sen *et al.*, 2004; Sen *et al.*, 2006), there seems to be somewhat of a consensus that γ - and δ -tocotrienols are the most potent anti-cancer isoform of all natural existing tocotrienols. One of the first studies addressing the role of tocotrienols in neoplastic

disorders was reported in 1989 (Komiyama *et al.*, 1989). The effects of intraperitoneally injected α - and γ -tocotrienol, as well as that of α -tocopherol, have been examined. Both tocotrienols were effective against sarcoma 180, Ehrlich carcinoma, and invasive mammary carcinoma. γ -Tocotrienol showed a slight life-prolonging effect in mice with Meth A fibrosarcoma, but the tocotrienols had no antitumor activity against P388 leukemia at doses of 5–40 mg/kg/d (Komiyama *et al.*, 1989). In contrast to tocotrienols, α -tocopherol was not as effective. The antitumor activity of γ -tocotrienol was higher than that of α -tocotrienol. In contrast to α -tocopherol, tocotrienols showed growth inhibition of human and mouse tumor cells when the cells were exposed to these agents for 72 h *in vitro* (Komiyama *et al.*, 1989). In an independent study published in the same year the anti-carcinogenic properties of palm oil, a rich source of tocotrienols, was reported (Sundram *et al.*, 1989). In this study, young female Sprague-Dawley rats were treated with a single dose of 5 mg of 7,12-dimethylbenz(a)anthracene intragastrically. Three days after carcinogen treatment, the rats were put on semisynthetic diets containing 20% by weight of corn oil, soybean oil, crude palm oil (CPO), refined, bleached, deodorized palm oil (RBD PO) and metabisulfite-treated palm oil (MCPO) for 5 months. During the course of experiments, rats fed on different dietary fats had similar rate of growth. Rats fed 20% corn oil or soybean oil diet had marginally higher tumor incidence than rats fed on palm oil diets. At autopsy, rats fed on high corn oil or soybean oil diets had significantly more tumors than rats fed on the three palm oil diets. Palm oil is different from corn oil and soybean oil in many ways. In addition to possessing higher levels of tocotrienol, palm oil has a contrasting fatty acid profile and also much higher levels of tocopherol and carotenes. As such, the favorable anti-carcinogenic effects noted in this study cannot be directly associated with tocotrienols (Sundram *et al.*, 1989). The antioxidant or redox property of tocotrienol is not responsible for its anti-cancer property. Results in support of this hypothesis show that a redox-silent analogue of α -tocotrienol, 6-O-carboxypropyl- α -tocotrienol is cytotoxic against A549 cells, a human lung adenocarcinoma cell line (Yano *et al.*, 2005). Although the phenolic antioxidant group in tocotrienol may not be implicated in its anticancer property, it is apparent that the phytol side chain has some antioxidant property which prevents against carcinogenesis (Yu *et al.*, 2005).

Breast cancer—Among the various forms of cancer, breast cancer has been most extensively studied in cell culture and rodent *in vivo* models for the efficacy of tocotrienols. Tocopherol and tocotrienol have been tested side-by-side for chemopreventive activity in a chemically induced rat mammary-tumor model. When mammary tumors were induced by 7,12-dimethylbenz(a)anthracene, only the tocotrienol group showed enhanced tumor latency (Gould *et al.*, 1991). The tocotrienol-rich fraction (TRF) of palm oil is not only rich in tocotrienols but also contains some α -tocopherol. The effects of TRF and α -tocopherol on the proliferation, growth, and plating efficiency of the MDA-MB-435 estrogen-receptor-negative human breast cancer cells have been examined (Nesaretnam *et al.*, 1995). TRF inhibited the proliferation of these cells with a concentration required to inhibit cell proliferation by 50% of 180 microgram/mL whereas α -tocopherol had no effect at concentrations up to 1000 microgram/mL. The effects of TRF and α -tocopherol were also tested in longer-term experiments, using concentrations of 180 and 500 microgram/mL. TRF, but not α -tocopherol, inhibited the growth as well as plating efficiency of the cells. These findings point towards the hypothesis that α -tocopherol contained in the TRF does not account for its beneficial effects and that tocotrienols may have been the active principle responsible for the observed effects of TRF (Nesaretnam *et al.*, 1995). It is now known that TRF, α -, γ - and δ -tocotrienols inhibited proliferation of estrogen receptor-negative MDA-MB-435 human breast cancer cells with 50% inhibitory concentrations (IC₅₀) of 180, 90, 30 and 90 microg/mL, respectively, whereas α -tocopherol is not effective at concentrations up to 500 microg/mL. Tocotrienols inhibit the proliferation of estrogen receptor-positive MCF-7 cells. The IC₅₀s for TRF, α -, γ - and δ -tocotrienols have been estimated to be 4, 6, 2 and 2 microg/mL, respectively. In sharp contrast, the efficiency of

α -tocopherol under comparable conditions is 20-50 times lower with a IC₅₀ of 125 microg/mL (Guthrie *et al.*, 1997). Tamoxifen, a widely used synthetic anti-estrogen inhibits the growth of MCF-7 cells with an IC₅₀ of 0.04 microg/mL. In the MCF-7 cells, only 1:1 combinations of γ - or δ -tocotrienol with tamoxifen showed a synergistic inhibitory effect on the proliferative rate and growth of the cells. α -Tocopherol did not exhibit this beneficial synergistic effect with tamoxifen (Guthrie *et al.*, 1997). The inhibition by tocotrienols was not overcome by addition of excess estradiol to the culture medium suggesting that tocotrienols are effective inhibitors of both estrogen receptor-negative and - positive cells and that combinations with tamoxifen may be useful for breast cancer therapy (Guthrie *et al.*, 1997). Studies to come would strengthen support for the case that tocotrienols are effective against breast cancer *in vitro*. TRF inhibits growth of MCF7 cells in both the presence and absence of estradiol such that complete suppression of growth is achieved at 8 microg/mL. MDA-MB-231 cells are also inhibited by TRF such that 20 microg/mL TRF is needed for complete growth suppression. The study of the individual component tocotrienols in TRF revealed that all fractions inhibit growth of both estrogen-responsive as well as estrogen-nonresponsive cells and of estrogen-responsive cells in both the presence and absence of estradiol. This estradiol-independent effect of tocotrienols is of clinical interest (Nesaretnam *et al.*, 2000; Nesaretnam *et al.*, 1998). γ - and δ -Tocotrienol fractions were most potent inhibitors of breast cancer cell growth. Complete inhibition of MCF7 cell growth was achieved at 6 microg/mL of γ -tocotrienol/ δ -tocotrienol in the absence of estradiol and 10 microg/mL of δ -tocotrienol in the presence of estradiol. In contrast, complete suppression of MDA-MB-231 cell growth was not achieved even at concentrations of 10 microg/mL of δ -tocotrienol. Of note, unlike tocotrienols α -tocopherol does not inhibit MCF7, MDA-MB-231 or ZR-75-1 cell growth in either the presence or the absence of estradiol (Mo and Elson 1999; Nesaretnam *et al.*, 2000; Nesaretnam *et al.*, 1998). Studies examining the mechanisms by which tocotrienols check the growth of breast cancer cells have identified that tocotrienols do not act via an estrogen receptor-mediated pathway and must therefore act differently from estrogen antagonists. Furthermore, tocotrienols did not increase levels of growth-inhibitory insulin-like growth factor binding proteins in MCF7 cells, implying also a different mechanism from that proposed for retinoic acid inhibition of estrogen-responsive breast cancer cell growth (Nesaretnam *et al.*, 1998).

Unlike α -tocopherol, δ -tocopherol seems to be more promising albeit much less so than the tocotrienols. The apoptosis-inducing properties of RRR- α -, β -, γ -, and δ -tocopherols, and α -, γ -, and δ -tocotrienols have been compared in estrogen-responsive MCF7 and estrogen-nonresponsive MDA-MB-435 human breast cancer cell lines. Vitamin E succinate, a known inducer of apoptosis in several cell lines, including human breast cancer cells, served as a positive control. The estrogen-responsive MCF7 cells was found to be more susceptible than the estrogen-nonresponsive MDA-MB-435 cells, with concentrations for half-maximal response for tocotrienols (α -, γ and δ) and RRR- δ -tocopherol of 14, 15, 7, and 97 micrograms/ml, respectively. The tocotrienols (α -, γ and δ) and RRR- δ -tocopherol induced MDA-MB-435 cells to undergo apoptosis, with concentrations for half-maximal response of 176, 28, 13, and 145 micrograms/ml, respectively. With the exception of RRR- δ -tocopherol, the tocopherols (α -, β -, and γ) and the acetate derivative of RRR- α -tocopherol (RRR- α -tocopheryl acetate) were ineffective in induction of apoptosis in both cell lines when tested within the range of their solubility, i.e., 10-200 micrograms/ml (Yu *et al.*, 1999)

Mammary tissue homeostasis depends upon dynamic interactions between the epithelial cells, their microenvironment (including the basement membrane and the stroma), and the tissue architecture, which influence each other reciprocally to regulate growth, death and differentiation in the gland. The study of normal mammary epithelial cells isolated from mid-pregnant mice grown in collagen gels and maintained on serum-free media showed that treatment with 0-120 microM α - or γ -tocopherol had no effect, whereas 12.5-100 microM

TRF, 100-120 microM δ -tocopherol, 50-60 microM α -tocotrienol, and 8-14 microM γ - or δ -tocotrienol significantly inhibited cell growth in a dose-responsive manner. In acute studies, 24h exposure to 0-250 microM α -, γ -, and δ -tocopherol had no effect, whereas similar treatment with 100-250 microM TRF, 140-250 microM α -, 25-100 microM γ - or δ -tocotrienol significantly reduced cell viability. The observed growth-inhibitory doses of TRF, δ -tocopherol, and α -, γ -, and δ -tocotrienol induced apoptosis in these cells. Mammary epithelial cells preferentially took up tocotrienols as compared to tocopherols, suggesting that at least part of the reason tocotrienols display greater potency than tocopherols is because of greater cellular uptake. These observations suggest that the highly biopotent γ - and δ -tocotrienol isoforms may play a physiological role in modulating normal mammary gland growth, function, and remodeling (McIntyre *et al.*, 2000b). A later study identified that highly malignant cells are specifically more sensitive, whereas the preneoplastic cells are least sensitive to the antiproliferative and apoptotic effects of tocotrienols (McIntyre *et al.*, 2000a). The comparative effects of tocopherols and tocotrienols were examined using preneoplastic (CL-S1), neoplastic (-SA), and highly malignant (+SA) mouse mammary epithelial cells. Over a five-day culture period, treatment with 0-120 microM α - and γ -tocopherol had no effect on cell proliferation, whereas cell growth was inhibited 50% (IC50) as compared with controls by treatment with the following: 13, 7, and 6 microM tocotrienol-rich-fraction of palm oil (TRF); 55, 47, and 23 microM δ -tocopherol; 12, 7, and 5 microM α -tocotrienol; 8, 5, and 4 microM γ -tocotrienol; or 7, 4, and 3 microM δ -tocotrienol in CL-S1, -SA and +SA cells, respectively. Acute 24-hr exposure to 0-250 microM α - or γ -tocopherol (CL-S1, -SA, and +SA) or 0-250 microM δ -tocopherol (CL-S1) had no effect on cell viability, whereas cell viability was reduced 50% (LD50) as compared with controls by treatment with 166 or 125 microM δ -tocopherol in -SA and +SA cells, respectively. Additional LD50 doses were determined as the following: 50, 43, and 38 microM TRF; 27, 28, and 23 microM α -tocotrienol; 19, 17, and 14 microM γ -tocotrienol; or 16, 15, or 12 microM δ -tocotrienol in CL-S1, -SA, and +SA cells, respectively. Treatment-induced cell death resulted from activation of apoptosis. Consistent with previous observations, CL-S1, -SA, and +SA cells preferentially accumulated tocotrienols as compared with tocopherols. Highly malignant +SA cells were the most sensitive, whereas the pre-neoplastic CL-S1 cells were the least sensitive to the anti-proliferative and apoptotic effects of tocotrienols (McIntyre *et al.*, 2000a).

How do tocotrienols induce apoptosis in breast cancer cells? δ -Tocotrienol induces TGF- β receptor II expression and activates TGF- β -, Fas- and JNK-signaling pathways. (Shun *et al.*, 2004). Are the caspase-3,8,9 pathways involved in tocotrienol-induced death of cancer cells? To respond to this question, highly malignant +SA mouse mammary epithelial cells were grown in culture and maintained on serum-free media. Treatment with TRF or γ -tocotrienol, but not α -tocopherol, induced a dose-dependent decrease in +SA cell viability (Shah *et al.*, 2003). TRF- and γ -tocotrienol-induced cell death resulted from apoptosis. Treatment of cells with TRF or γ -tocotrienol increased intracellular activity and levels of processed caspase-8 and -3 but not caspase-9. Furthermore, treatment with specific caspase-8 or -3 inhibitors, but not caspase-9 inhibitor, completely blocked tocotrienol-induced apoptosis in +SA cells suggesting that tocotrienol-induced apoptosis in +SA mammary cancer cells is mediated through activation of the caspase-8 signaling pathway and is independent of caspase-9 activation (Shah *et al.*, 2003). Tocotrienol-induced caspase 8 activation is not associated with death receptor apoptotic signaling (Shah and Sylvester 2004). γ -Tocotrienol significantly decreases the relative intracellular levels of phospho-phosphatidylinositol 3-kinase (PI3K)-dependent kinase 1 (phospho-PDK-1 active), phospho-Akt (active), and phospho-glycogen synthase kinase3. It also decreases the intracellular levels of FLICE-inhibitory protein (FLIP), an antiapoptotic protein that inhibits caspase-8 activation. Because stimulation of the PI3K/PDK/Akt mitogenic pathway is associated with increased FLIP expression, enhanced cellular proliferation, and survival, these observations suggest that tocotrienol-induced caspase-8

activation and apoptosis in malignant +SA mammary epithelial cells is associated with a suppression in PI3K/PDK-1/Akt mitogenic signaling and subsequent reduction in intracellular FLIP levels (Shah and Sylvester 2004). More recently it has been reported that the antiproliferative effects of γ -tocotrienol results, at least in part, from a reduction in Akt and NFkappaB activity in neoplastic +SA mammary epithelial cells (Shah and Sylvester 2005a).

α -Tocotrienol (20 microM) seems to share some of the cytotoxic effects on cancer cells by inducing caspase-8 and caspase-3 activity (Sylvester and Shah 2005a). Combined treatment with specific caspase-8 or caspase-3 inhibitors completely blocked α -tocotrienol-induced apoptosis and caspase-8 or caspase-3 activity, respectively. In contrast, α -tocotrienol treatment had no effect on caspase-9 activation, and combined treatment with a specific caspase-9 inhibitor did not block α -tocotrienol-induced apoptosis in +SA cells. α -Tocotrienol-induced caspase-8 activation and apoptosis is not mediated through death receptor activation in malignant +SA mammary epithelial cells. Tocotrienol-induced caspase-8 activation and apoptosis in malignant +SA mammary epithelial cells is not mediated through the activation of death receptors, but appears to result from the suppression of the PI3K/PDK/Akt mitogenic signaling pathway, and subsequent reduction in intracellular FLIP expression (Sylvester and Shah 2005a).

Bcl-2 family proteins tightly control apoptosis by regulating the permeabilization of the mitochondrial outer membrane and, hence, the release of cytochrome c and other proapoptotic factors. Is tocotrienol-induced apoptosis of cancer cells dependent on mitochondrial pathways? Incubation of MDA-MB-231 cells with γ -tocotrienol causes membrane blebbing, formation of apoptotic bodies, chromatin condensation/fragmentation, and phosphatidylserine externalization (Takahashi and Loo 2004). These are all hallmarks of apoptosis. In γ -tocotrienol-treated cells, mitochondria were disrupted. Collapse of the mitochondrial membrane potential was followed by the release of mitochondrial cytochrome c. However, the expression of Bax and Bcl-2 mRNA and protein did not change. In contrast to other studies reporting that tocotrienol-induced cell death is caspase dependent (Shah *et al.*, 2003; Shah and Sylvester 2004), it was noted that in this model caspases were not involved in γ -tocotrienol-induced apoptosis (Takahashi and Loo 2004). In a study of +SA cells it was noted that although γ -tocotrienol induced apoptosis it did not disrupt mitochondrial membrane potential, or cause the release of mitochondrial cytochrome c into the cytoplasm. Tocotrienol-treated apoptotic +SA cells showed a paradoxical decrease in mitochondrial levels of pro-apoptotic proteins Bid, Bax, and Bad, and a corresponding increase in mitochondrial levels of anti-apoptotic proteins, Bcl-2 and Bcl-xL, suggesting that mitochondrial membrane stability and integrity might actually be enhanced for a limited period of time following acute tocotrienol exposure. This significance of this unusual finding remains obscure (Shah and Sylvester 2005b)

Over the past 30 years, a relatively simple growth factor and its cognate receptor have provided seminal insights into the understanding of the genetic basis of cancer, as well as growth factor signaling. The epidermal growth factor (EGF), its cognate receptor (EGFR) and related family members have been shown to be important in normal, as well as the malignant growth of many cell types including breast cancer. EGF is a potent mitogen for normal and neoplastic mammary epithelial cells. Initial events in EGFR mitogenic-signaling are G-protein activation, stimulation of adenylyl cyclase and cyclic AMP (cAMP) production. Do the antiproliferative effects of tocotrienols associate with reduced EGF-induced G-protein and cAMP-dependent mitogenic signaling? To answer this question, preneoplastic CL-S1 mouse mammary epithelial cells were grown in culture and maintained on serum-free media containing 0-25 micro mol/L tocotrienol-rich fraction of palm oil and/or different doses of pharmacological agents that alter intracellular cAMP levels. Tocotrienol-induced effects on EGF-receptor levels of tyrosine kinase activity, as well as EGF-dependent mitogen-activated pathway kinase (MAPK) and Akt activation, were examined. It was noted that the anti-proliferative effects of tocotrienols in pre-

neoplastic mammary epithelial cells do not reflect a reduction in EGF-receptor mitogenic responsiveness, but rather, result from an inhibition in early post-receptor events involved in cAMP production upstream from EGF-dependent MAPK and phosphoinositide 3-kinase/Akt mitogenic signaling (Sylvester *et al.*, 2002).

7,12-Dimethylbenz[a]anthracene (DMBA) is a potent inducer breast cancer in rats. The anti-tumour and anti-cholesterol impacts of has been examined in rats treated with the chemical carcinogen DMBA, which is known to induce mammary carcinogenesis and hypercholesterolemia. DMBA induced multiple tumors on mammary glands after 6 months. Feeding of TRF (10 mg/kg body weight/day) for 6 months, isolated from rice bran oil, to DMBA-administered rats, attenuated the severity and extent of neoplastic transformation in the mammary glands. Consistently, plasma and mammary alkaline phosphatase activities increased during carcinogenesis, were significantly decreased in TRF-treated rats. TRF treatment to rats maintained low levels of glutathione S-transferase activities in liver and mammary glands, which is consistent with the anti-carcinogenic properties of TRF (Iqbal *et al.*, 2003). Administration of DMBA also caused a significant increase of 30% in plasma total cholesterol and 111% in LDL-cholesterol levels compared with normal control levels. Feeding of TRF to rats caused a significant decline of 30% in total cholesterol and 67% in LDL-cholesterol levels compared with the DMBA-administered rats. The experimental hypercholesterolaemia caused a significant increase in enzymatic activity (23%) and protein mass (28%) of hepatic 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase. Consistent with TRF-mediated reduction in plasma lipid levels, enzymatic activity and protein mass of HMG-CoA reductase was significantly reduced. These observations support that TRF has potent anti-cancer and anti-cholesterol effects in rats (Iqbal *et al.*, 2003).

Tocotrienols act on cell proliferation in a dose-dependent manner and can induce programmed cell death in breast cancer cells. To elucidate the molecular basis of the effect of tocotrienols, MCF-7 breast cancer cells were injected into athymic nude mice. Feeding quite large amounts (1mg/d) of TRF for 20 weeks delayed the onset, incidence, and size of tumors. At autopsy, the tumor tissue was excised and cDNA array analysis was performed. Thirty out of 1176 genes were significantly affected by TRF. Ten genes were down-regulated and 20 genes up-regulated with respect to untreated animals. The expression of the interferon-inducible transmembrane protein-1 gene was significantly up-regulated in tumors excised from TRF-treated animals compared with control mice. Within the group of genes related to the immune system, CD59 glycoprotein precursor gene was up-regulated. Among the functional class of intracellular transducers/effectors/modulators, the c-myc gene was significantly down-regulated in tumors in response to TRF treatment. This work on the survey of TRF-sensitive genes in the tumor in vivo presented useful insight (Nesaretnam *et al.*, 2004).

Prostate—Unlike the literature on breast cancer cells, work on prostate cancer cells investigating the effect of tocotrienol is scant. In a model where prostate cancer was induced by injecting PC3 cells into nude BALB/c mice, it has been noted that the radiotherapy efficacy of prostate cancer can be increased with γ -tocotrienol and a pro-oxidant if the kidneys can be shielded (Kumar *et al.*, 2006). When the tumors were about 5 mm in diameter, mice were injected subcutaneously with 400 mg/kg γ -tocotrienol and irradiated 24 h later at the site of the tumor with a dose of 12 Gy (60) Cobalt. The size of the tumors was reduced by almost 40%, but only in tocotrienol-treated and irradiated mice (Kumar *et al.*, 2006). The growth-inhibitory and apoptotic effects of TRF has been tested on normal human prostate epithelial cells (PrEC), virally transformed normal human prostate epithelial cells (PZ-HPV-7), and human prostate cancer cells (LNCaP, DU145, and PC-3) (Srivastava and Gupta 2006). TRF selectively resulted in potent growth inhibition in cancer cells but not normal cells. In response to TRF, cancer cells underwent G0/G1 phase arrest and sub G1 accumulation. Colony formation by all three prostate cancer cell lines studied was clearly arrested by TRF. The IC

(50) after 24h TRF treatment in LNCaP, PC-3, and DU145 cells were in the order 16.5, 17.5, and 22.0 microg/ml. TRF treatment resulted in significant apoptosis of cancer cells but not of normal cells (Srivastava and Gupta 2006).

Immune system—Inhibition of tumor promotion by tocopherols and tocotrienols was examined by an in vitro assay utilizing the activation of Epstein-Barr virus early antigen expression in Epstein-Barr virus genome-carrying human lymphoblastoid cells. γ - and δ -Tocotrienols derived from palm oil exhibited a strong activity against tumor promotion by inhibiting Epstein-Barr virus early antigen expression in Raji cells induced by 12-O-tetradecanoylphorbol-13-acetate. In contrast, the corresponding tocopherols lacked this activity (Goh *et al.*, 1994).

Liver—Tocotrienol inhibits the growth of hepatoma cells but not that of hepatocytes from healthy rat liver (Sakai *et al.*, 2004). Consistently, tocotrienol killed murine liver cancer cells but not normal cells (Har and Keong 2005). Of note, this interesting function of tocotrienol is not shared by tocopherol. Tocotrienol induced apoptosis of hepatoma cells is mediated by caspase 3 activation. In addition, tocotrienol induced caspase 8 activity. An inhibitor of caspase 8 suppressed the induction of apoptosis in hepatoma by tocotrienol. Compared to tocopherol, tocotrienol was more quickly taken up by the cancer cells suggesting that this could be one reason why tocotrienol was so effective in killing the hepatoma cells (Har and Keong 2005; Sakai *et al.*, 2004). γ -Tocotrienol inhibits the proliferation of human hepatoma Hep3B cells at lower concentrations and shorter treatment times than α -tocotrienol. γ -Tocotrienol induces poly (ADP-ribose) polymerase (PARP) cleavage activating caspase-3. In addition, γ -tocotrienol activates caspase-8 and caspase-9 and up-regulates Bax and fragments of Bid (Sakai *et al.*, 2005). In human hepatocellular carcinoma HepG2 cells, δ -tocotrienol exerts more significant anti-proliferative effect than α -, β -, and γ -tocotrienols. δ -Tocotrienol induced apoptosis, and also tended to induce S phase arrest. The phase I enzyme CYP1A1 was induced by δ -tocotrienol (Wada *et al.*, 2005).

2-Acetylaminofluorene is a potent hepatocarcinogen. Prolonged feeding of rats with 2-acetylaminofluorene causes hepatocellular damage. Such damage is prevented by tocotrienol supplementation (Ngha *et al.*, 1991). 2-Acetylaminofluorene significantly increased the activities of both plasma and liver microsomal γ -glutamyltranspeptidase (GGT) and liver microsomal UDP-glucuronyltransferase (UDP-GT). Tocotrienols administered together with AAF significantly decrease the activities of plasma GGT after 12 and 20 wk and liver microsomal UDP-GT after 20 wk when compared with matched controls (Ngha *et al.*, 1991). In a scenario of stronger chemical carcinogen insult caused by 2-acetylaminofluorene in conjunction with diethylnitrosamine the effects of tocotrienol turned out to be more encouraging. In response to challenge by the chemical carcinogens all ten rats in the group showed the presence of two grayish white nodules in the liver. Rats subjected to long-term administration of tocotrienol were protected. Only one out of six rats studied in this group had the hepatocarcinoma (Rahmat *et al.*, 1993)

The anticancer efficacy of TRF has been evaluated during diethylnitrosamine (DEN)/2-acetylaminofluorene (AAF)-induced hepatocarcinogenesis in male Sprague-Dawley rats. TRF treatment was carried out for 6 months, and was started 2 weeks before the initiation phase of hepatocarcinogenesis. Morphological examination of the livers from DEN/AAF rats showed numerous off-white patches and few small nodules, which were significantly reduced by TRF treatment. DEN/AAF caused a two-fold increase in the activity of alkaline phosphatase in the plasma as compared with normal control rats. This increase of the tissue damage marker was prevented significantly by TRF treatment. Hepatic activity of glutathione S-transferase was also increased (3.5-fold) during the induction of hepatic carcinogenesis. Lipid peroxidation

and low-density lipoprotein oxidation increased three-fold following initiation by DEN/AAF as compared with normal control rats. TRF treatment to DEN/AAF-treated rats substantially decreased (62-66%) the above parameters and thus limited the action of DEN/AAF. Thus, TRF exhibited clear protective properties in this model of chemical carcinogenesis (Iqbal *et al.*, 2004).

Gastrointestinal tract—RKO, a poorly differentiated colon carcinoma cell line, represents a commonly used in vitro model for human colon carcinoma. RKO cells contain wild-type p53 but lack endogenous human thyroid receptor nuclear receptor (h-TRbeta1). In a dose- and time-dependent manner TRF inhibited the growth and colony formation of RKO. In addition, TRF induced WAF1/p21 which appeared to be independent of cell cycle regulation and was transcriptionally up-regulated in p53 dependent fashion. TRF treatment also resulted in alteration in Bax/Bcl2 ratio in favor of apoptosis, which was associated with the release of cytochrome c and induction of apoptotic protease-activating factor-1. This altered expression of Bcl2 family members triggered the activation of initiator caspase-9 followed by activation of effector caspase-3. Thus, in RKO cells the pathways involved in TRF-induced apoptosis is fairly well characterized (Agarwal *et al.*, 2004). Since the discovery that telomerase is repressed in most normal human somatic cells but strongly expressed in most human tumors, telomerase emerged as an attractive target for diagnostic, prognostic and therapeutic purposes to combat human cancer (Shay and Wright 2006). Tocotrienol has been noted to inhibit telomerase activity of DLD-1 human colorectal adenocarcinoma cells in a time- and dose-dependent manner. δ -Tocotrienol demonstrated the highest inhibitory activity. Tocotrienol inhibited protein kinase C activity, resulting in down-regulation of c-myc and human telomerase reverse transcriptase (hTERT) expression, thereby reducing telomerase activity. Of note, tocopherol does not share the potent activity of tocotrienol in this regard (Shay and Wright 2006).

Skin—How much tocotrienol is needed to inhibit the increase in population of murine B16 (F10) melanoma cells during a 48-h incubation by 50% (IC₅₀ value)? The IC₅₀ value estimated for farnesol, the side-chain analog of the tocotrienols (50 micromol/L) falls midway between that of α -tocotrienol (110 micromol/L) and those estimated for γ - (20 micromol/L) and δ - (10 micromol/L) tocotrienol. Experimental diets were fed to weanling C57BL female mice for 10 d prior to and 28 d following the implantation of the aggressively growing and highly metastatic B16(F10) melanoma. The isomolar (116 micromol/kg diet) and the vitamin E-equivalent (928 micromol/kg diet) substitution of d- γ -tocotrienol for dl- α -tocopherol in the AIN-76A diet produced 36 and 50% retardations, respectively, in tumor growth. Thus, in this skin melanoma model both tocotrienol as well as tocopherol were significantly effective (He *et al.*, 1997). The growth suppressive effects of γ -tocotrienol on murine B16(F10) melanoma cells have been independently reproduced (Mo and Elson 1999).

Recent works have led to the identification of anti-angiogenic properties of tocotrienol (see Table 1). This novel development warrants further research testing the anti-cancer effects of tocotrienol *in vivo*.

c. Cholesterol lowering

That the α -tocotrienol form of natural vitamin E, not tocopherol, may have significant cholesterol-lowering properties represents one of the early findings describing the unique biological properties of tocotrienol that was reported two decades ago (Qureshi *et al.*, 1986). The endoplasmic reticulum enzyme 3-hydroxy-3-methylglutaryl (HMG-CoA) CoA reductase produces mevalonate, which is converted to sterols and other products. It is proposed that tocotrienols are effective in lowering serum total and LDL-cholesterol levels by inhibiting the hepatic enzymic activity of HMG-CoA reductase through a post-transcriptional mechanism. α -Tocopherol, however, has an opposite effect (induces) on this enzyme activity (Qureshi *et*

et al., 2002). This contrast is of outstanding significance and requires further characterization. α -Tocotrienol, contained in the oily non-polar fraction of high protein barley (*Hordeum vulgare* L.) flour, decreased hepatic cholesterogenesis and serum total and low density lipoprotein cholesterol and concomitantly increased lipogenic activity when added to chick diet. It was suspected that the isoprenoid side-chain of tocotrienol was responsible for the observed inhibition of cholesterogenesis (Qureshi *et al.*, 1986). Evidence that TRF may indeed lower plasma cholesterol in mammals came from a study of normolipemic and genetically hypercholesterolemic pigs of defined lipoprotein genotype (Qureshi *et al.*, 1991a). The pigs were fed a standard diet supplemented with 50 micrograms/g TRF isolated from palm oil. Hypercholesterolemic pigs fed the TRF supplement showed a 44% decrease in total serum cholesterol, a 60% decrease in LDL-cholesterol, and significant decreases in levels of apolipoprotein B (26%), thromboxane-B2 (41%), and platelet factor 4 (PF4; 29%). It was thus noted that TRF had a marked protective effect on the endothelium and platelet aggregation. The effect of the lipid-lowering diet persisted only in the hypercholesterolemic swine after 8 week feeding of the control diet (Qureshi *et al.*, 1991a). These interesting observations were quickly put to test in humans by means of a double-blind, crossover, 8-week study (Qureshi *et al.*, 1991b). The goal was to compare effects of the tocotrienol-enriched fraction of palm oil (200 mg palmvitee capsules/day) with those of 300 mg corn oil/d on serum lipids of hypercholesterolemic human subjects (serum cholesterol 6.21-8.02 mmol/L). Concentrations of serum total cholesterol (-15%), LDL cholesterol (-8%), Apo B (-10%), thromboxane (-25%), platelet factor 4 (-16%), and glucose (-12%) decreased significantly only in the 15 subjects given palmvitee during the initial 4 wk. Results from the crossover study established that the noted beneficial effects were indeed caused by palmvitee. A carry-over effect of palmvitee was reported. Serum cholesterol concentrations of seven hypercholesterolemic subjects (>7.84 mmol/L) decreased 31% during a 4 wk period in which they were given 200 mg γ -tocotrienol/d. These results suggested that γ -tocotrienol could be the active principle cholesterol inhibitor in palmvitee capsules (Qureshi *et al.*, 1991b). Experimental data from the study of hamsters are in agreement (Raederstorff *et al.*, 2002). What added to the interest in tocotrienol as a cholesterol-lowering nutrient in humans was a concurrent independent study reporting the hypocholesterolemic effects of palmvitee (Tan *et al.*, 1991). Each palmvitee capsule contained approximately 18, 42, and 240 mg of tocopherols, tocotrienols, and palm olein, respectively. All volunteers took one palmvitee capsule per day for 30 consecutive days. Overnight fasting blood was recorded from each volunteer before and after the experiment. Palmvitee lowered both serum total cholesterol and low-density-lipoprotein cholesterol concentrations in all subjects. The magnitude of reduction of serum total cholesterol ranged from 5.0% to 35.9% whereas the reduction of low-density-lipoprotein cholesterol values ranged from 0.9% to 37.0% when compared with their respective baseline values (Tan *et al.*, 1991). In another study, the cholesterol-lowering effects of palmvitee and γ -tocotrienol were examined in hypercholesterolemic subjects after acclimation to the American Heart Association Step 1 dietary regimen for four and eight weeks, respectively (Qureshi *et al.*, 1995). The four-week dietary regimen alone elicited a 5% significant decrease in the cholesterol level of the 36 subjects. Subjects continuing on the dietary regimen for a second four-week period benefited from an additional 2% decrease in their cholesterol levels. The subjects experienced significant palmvitee- and γ -tocotrienol-mediated decreases in plasma cholesterol. The group of subjects acclimated to the dietary regimen for four weeks responded to palmvitee with a 10% statistically significant decrease in cholesterol. Of interest, α -tocopherol attenuated the cholesterol-suppressive action of the tocotrienols. This antagonism between tocopherol and tocotrienol warrants further research. The second group of subjects acclimated to the dietary regimen for eight weeks, received 200 mg γ -tocotrienol/d for four weeks. The cholesterol-suppressive potency of this α -tocopherol-free preparation was calculated to be equivalent to that of the mixture of tocotrienols (220 mg) used in the prior study. Cholesterol levels of the 16 subjects in the second group significantly decreased by 13% during the four-week trial.

Plasma apolipoprotein B and ex vivo generation of thromboxane B2 were similarly responsive to the tocotrienol preparations, whereas neither preparation had an impact on high density lipoprotein cholesterol and apolipoprotein A-1 levels (Qureshi *et al.*, 1995).

Tocotrienol not only of palm oil origin but also isolated from rice bran show cholesterol-lowering properties (Chen and Cheng 2006; Qureshi *et al.*, 2001a). A human study with 28 hypercholesterolemic subjects has been executed in 5 phases of 35 days each. The goal was to check the efficacy of a TRF preparation from rice bran alone and in combination with lovastatin. After placing subjects on the American Heart Association (AHA) Step-1 diet (phase II), the subjects were divided into two groups, A and B. The AHA Step-1 diet was continued in combination with other treatments during phases III to V. Group A subjects were given 10 mg lovastatin, 10 mg lovastatin plus 50 mg TRF, 10 mg lovastatin plus 50 mg α -tocopherol per day, in the third, fourth, and fifth phases, respectively. Group B subjects were treated exactly according to the same protocol except that in the third phase, they were given 50 mg TRF instead of lovastatin. The TRF or lovastatin plus AHA Step-1 diet effectively lowered serum total cholesterol (14%, 13%) and LDL-cholesterol (18%, 15%), respectively. The combination of TRF and lovastatin plus AHA Step-1 diet significantly reduced the lipid parameters by 20-25%. Especially significant were the increase in the HDL/LDL ratio to 46% in group A and 53% in group B. None of the subjects reported any side-effects throughout the study of 25 weeks (Qureshi *et al.*, 2001c). Consistent results were obtained using rice-bran derived TRF in another human study (Qureshi *et al.*, 2002). A dose of 100 mg/day of TRF decreased the level of serum total cholesterol, LDL-cholesterol, apolipoprotein B and triglycerides compared with the baseline values. The work led to the suggestion that a dose of 100 mg/day TRF plus AHA Step-1 diet could control the risk of coronary heart disease in hypercholesterolemic humans (Qureshi *et al.*, 2002).

Mechanistic evidence supporting the cholesterol-lowering properties of tocotrienol is considerable. Tocotrienols cause post-transcriptional suppression of HMG-CoA reductase by a process distinct from other known inhibitors of cholesterol biosynthesis (Pearce *et al.*, 1992). In addition, γ -tocotrienol may stimulate cholesterol catabolism (Chen and Cheng 2006). *In vitro*, γ -tocotrienol possesses 30-fold greater activity toward cholesterol biosynthesis inhibition compared to α -tocotrienol. The synthetic (racemic) and natural (chiral) tocotrienols exhibited nearly identical cholesterol biosynthesis inhibition and HMG-CoA reductase suppression properties (Pearce *et al.*, 1992). Incubation of several cell-types with γ -tocotrienol inhibits the rate of [¹⁴C]acetate but not [³H] mevalonate incorporation into cholesterol in a concentration- and time-dependent manner, with 50% inhibition at approximately 2 μ M and maximum approximately 80% inhibition observed within 6 h in HepG2 cells (Parker *et al.*, 1993). Both HMG-CoA reductase activity and protein expression are sensitive to tocotrienol. *In vivo* studies lend support to that *in vitro* observation (Iqbal *et al.*, 2003). Tocotrienols influence the mevalonate pathway in mammalian cells by post-transcriptional suppression of HMG-CoA reductase, and specifically modulate the intracellular mechanism for controlled degradation of the reductase protein, an activity that mirrors the actions of the putative non-sterol isoprenoid regulators derived from mevalonate (Parker *et al.*, 1993). It is suggested that the farnesyl side chain and the methyl/hydroxy substitution pattern of γ -tocotrienol deliver a high level of HMG-CoA reductase suppression, unsurpassed by synthetic analogues studied (Pearce *et al.*, 1994). HMG-CoA reductase activity in tumor tissues differs from that of liver in being resistant to sterol feedback regulation. Tumor reductase activity retains sensitivity to the post-transcriptional regulation. As a consequence, tocotrienol is effective in suppressing mevalonate synthesis. By doing so, tocotrienol can deplete tumor tissues of two intermediate products, farnesyl pyrophosphate and geranylgeranyl pyrophosphate, which are incorporated post-translationally into growth control-associated proteins (Elson and Qureshi 1995).

Ubiquitination followed by rapid degradation by 26S proteasomes represents a key mechanism to silence HMG-CoA reductase. This pathway is activated when sterols and non-sterol end products of mevalonate metabolism accumulate in cells. Sterol-accelerated ubiquitination of HMG-CoA reductase requires Insig-1 and Insig-2, membrane-bound proteins of the endoplasmic reticulum (Sever *et al.*, 2003). Recently it has been elegantly demonstrated that δ -tocotrienol stimulates the ubiquitination and degradation of HMG-CoA reductase and blocks processing of sterol regulatory element-binding proteins, another sterol-mediated action of Insigs. The γ -tocotrienol analog was noted to be more selective in enhancing reductase ubiquitination and degradation than blocking the processing of sterol regulatory element-binding proteins. Interestingly, other forms of vitamin E neither accelerate reductase degradation nor block the processing of sterol regulatory element-binding proteins. δ - and γ -Tocotrienol trigger reductase ubiquitination directly and do not require further metabolism for their activity (Song and Debose-Boyd 2006).

VIII. Conclusion

Often, the term vitamin E is synonymously used with α -tocopherol. While the expression is correct it is incomplete and may be often misleading. d- α -Tocopherol (RRR- α -tocopherol) has the highest bioavailability and is the standard against which all the others must be compared. However, it is only one out of eight natural forms of vitamin E. The rapidly expanding body of evidence indicating that members of the vitamin E family are functionally unique calls for a revisit of the current practices in vitamin E research and consumption. Research claims should be limited to the specific form of vitamin E studied. For example, evidence for toxicity of a specific form of tocopherol in excess may not be used to conclude that high-dosage vitamin E supplementation may increase all-cause mortality (Miller *et al.*, 2005). Along these lines, it may not be prudent to express frustrations about the net yield of vitamin E research as a whole (Greenberg 2005) when all that has been tested for efficacy on a limited basis in clinical trials is α -tocopherol- just one out of eight forms. Recently it has been suggested that the safe dose of various tocotrienols for human consumption is 200-1000 mg/d (Yu *et al.*, 2006). Vitamin E represents one of the most fascinating natural resources that have the potential to influence a broad range of mechanisms underlying human health and disease. Yet, clinical outcomes studies have failed to meet expectations (Friedrich 2004; Greenberg 2005). The current state of knowledge warrants strategic investment into the lesser known forms of vitamin E with emphasis on uncovering the specific conditions that govern the function of vitamin E molecules *in vivo*. Outcome studies designed in light of such information would yield lucrative returns.

Acknowledgments

Tocotrienol research in the laboratory is supported by NIH RO1NS42617.

LITERATURE CITED

- Adachi H, Ishii N. Effects of tocotrienols on life span and protein carbonylation in *Caenorhabditis elegans*. *Journals of Gerontology Series A, Biological Sciences & Medical Sciences*. 2000; 55:B280–285.
- Adachi K, Miki M, Tamai H, Tokuda M, Mino M. Adipose tissues and vitamin E. *J Nutr Sci Vitaminol (Tokyo)*. 1990; 36:327–337. [PubMed: 2081975]
- Adesuyi SA, Cockrell CS, Gamache DA, Ellis EF. Lipoxygenase metabolism of arachidonic acid in brain. *J Neurochem*. 1985; 45:770–776. [PubMed: 3928809]
- Agarwal MK, Agarwal ML, Athar M, Gupta S. Tocotrienol-rich fraction of palm oil activates p53, modulates Bax/Bcl2 ratio and induces apoptosis independent of cell cycle association. *Cell Cycle*. 2004; 3:205–211. [PubMed: 14712090]

- Ahmad NS, Khalid BA, Luke DA, Ima Nirwana S. Tocotrienol offers better protection than tocopherol from free radical-induced damage of rat bone. *Clin Exp Pharmacol Physiol*. 2005; 32:761–770. [PubMed: 16173934]
- Aikawa R, Komuro I, Yamazaki T, Zou Y, Kudoh S, Tanaka M, Shiojima I, Hiroi Y, Yazaki Y. Oxidative stress activates extracellular signal-regulated kinases through Src and Ras in cultured cardiac myocytes of neonatal rats. *Journal of Clinical Investigation*. 1997; 100:1813–1821. [PubMed: 9312182]
- Alper O, Bowden ET. Novel insights into c-Src. *Curr Pharm Des*. 2005; 11:1119–1130. [PubMed: 15853660]
- Anderson SL, Qiu J, Rubin BY. Tocotrienols induce IKBKAP expression: a possible therapy for familial dysautonomia. *Biochem Biophys Res Commun*. 2003; 306:303–309. [PubMed: 12788105]
- Anderson SL, Rubin BY. Tocotrienols reverse IKAP and monoamine oxidase deficiencies in familial dysautonomia. *Biochem Biophys Res Commun*. 2005; 336:150–156. [PubMed: 16125677]
- Araya H, Tomita M, Hayashi M. The novel formulation design of self-emulsifying drug delivery systems (SEDDS) type O/W microemulsion III: the permeation mechanism of a poorly water soluble drug entrapped O/W microemulsion in rat isolated intestinal membrane by the Ussing chamber method. *Drug Metab Pharmacokinet*. 2006; 21:45–53. [PubMed: 16547393]
- Aten RF, Kolodecik TR, Behrman HR. Ovarian vitamin E accumulation: evidence for a role of lipoproteins. *Endocrinology*. 1994; 135:533–539. [PubMed: 8033800]
- Atkinson, J. Chemical investigations of tocotrienols: isotope substitution, fluorophores and a curious curve. Nesaretnam, K., editor. *Kuching, Malaysia: COSTAM*; 2006. p. 22
- Azlina MF, Nafeeza MI, Khalid BA. A comparison between tocopherol and tocotrienol effects on gastric parameters in rats exposed to stress. *Asia Pac J Clin Nutr*. 2005; 14:358–365. [PubMed: 16326642]
- Azzi A, Boscoboinik D, Marilley D, Ozer NK, Stauble B, Tasinato A. Vitamin E: a sensor and an information transducer of the cell oxidation state. *Am J Clin Nutr*. 1995; 62:1337S–1346S. [PubMed: 7495229]
- Azzi A, Stocker A. Vitamin E: non-antioxidant roles. *Progress in Lipid Research*. 2000; 39:231–255. [PubMed: 10799717]
- Bains JS, Shaw CA. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. *Brain Research - Brain Research Reviews*. 1997; 25:335–358. [PubMed: 9495562]
- Baliarsingh S, Beg ZH, Ahmad J. The therapeutic impacts of tocotrienols in type 2 diabetic patients with hyperlipidemia. *Atherosclerosis*. 2005; 182:367–374. [PubMed: 16159610]
- Bazan NG. Free arachidonic acid and other lipids in the nervous system during early ischemia and after electroshock. *Adv Exp Med Biol*. 1976; 72:317–335. [PubMed: 821317]
- Bazan NG Jr. Effects of ischemia and electroconvulsive shock on free fatty acid pool in the brain. *Biochim Biophys Acta*. 1970; 218:1–10. [PubMed: 5473492]
- Bazan NG Jr. Changes in free fatty acids of brain by drug-induced convulsions, electroshock and anaesthesia. *J Neurochem*. 1971a; 18:1379–1385. [PubMed: 4328510]
- Bazan NG Jr. Phospholipases A 1 and A 2 in brain subcellular fractions. *Acta Physiol Lat Am*. 1971b; 21:101–106. [PubMed: 5143304]
- Bazan NG Jr, Rakowski H. Increased levels of brain free fatty acids after electroconvulsive shock. *Life Sci*. 1970; 9:501–507. [PubMed: 5452521]
- Begum AN, Terao J. Protective effect of alpha-tocotrienol against free radical-induced impairment of erythrocyte deformability. *Biosci Biotechnol Biochem*. 2002; 66:398–403. [PubMed: 11999415]
- Bhat NR, Zhang P. Hydrogen peroxide activation of multiple mitogen-activated protein kinases in an oligodendrocyte cell line: role of extracellular signal-regulated kinase in hydrogen peroxide-induced cell death. *Journal of Neurochemistry*. 1999; 72:112–119. [PubMed: 9886061]
- Birringer M, EyTina JH, Salvatore BA, Neuzil J. Vitamin E analogues as inducers of apoptosis: structure-function relation. *Br J Cancer*. 2003; 88:1948–1955. [PubMed: 12799642]
- Birringer M, Pfluger P, Kluth D, Landes N, Brigelius-Flohe R. Identities and differences in the metabolism of tocotrienols and tocopherols in HepG2 cells. *J Nutr*. 2002; 132:3113–3118. [PubMed: 12368403]

- Black TM, Wang P, Maeda N, Coleman RA. Palm tocotrienols protect ApoE +/- mice from diet-induced atheroma formation. *J Nutr.* 2000; 130:2420–2426. [PubMed: 11015467]
- Blatt DH, Leonard SW, Traber MG. Vitamin E kinetics and the function of tocopherol regulatory proteins. *Nutrition.* 2001; 17:799–805. [PubMed: 11684383]
- Borngraber S, Browner M, Gillmor S, Gerth C, Anton M, Fletterick R, Kuhn H. Shape and specificity in mammalian 15-lipoxygenase active site. The functional interplay of sequence determinants for the reaction specificity. *J Biol Chem.* 1999; 274:37345–37350. [PubMed: 10601303]
- Boscoboinik D, Szewczyk A, Hensey C, Azzi A. Inhibition of cell proliferation by alpha-tocopherol. Role of protein kinase C. *J Biol Chem.* 1991; 266:6188–6194. [PubMed: 2007576]
- Brugge JS, Cotton PC, Queral AE, Barrett JN, Nonner D, Keane RW. Neurones express high levels of a structurally modified, activated form of pp60c-src. *Nature.* 1985; 316:554–557. [PubMed: 2412121]
- Bruno RS, Traber MG. Vitamin E biokinetics, oxidative stress and cigarette smoking. *Pathophysiology.* 2006; 13:143–149. [PubMed: 16814530]
- Bryngelsson S, Dimberg LH, Kamal-Eldin A. Effects of commercial processing on levels of antioxidants in oats (*Avena sativa* L.). *J Agric Food Chem.* 2002; 50:1890–1896. [PubMed: 11902929]
- Cahoon EB, Hall SE, Ripp KG, Ganzke TS, Hitz WD, Coughlan SJ. Metabolic redesign of vitamin E biosynthesis in plants for tocotrienol production and increased antioxidant content. *Nat Biotechnol.* 2003; 21:1082–1087. [PubMed: 12897790]
- Carlen PL, Gurevich N, Zhang L, Wu PH, Reynaud D, Pace-Asciak CR. Formation and electrophysiological actions of the arachidonic acid metabolites, hepoxilins, at nanomolar concentrations in rat hippocampal slices. *Neuroscience.* 1994; 58:493–502. [PubMed: 7909586]
- Chao JT, Gapor A, Theriault A. Inhibitory effect of delta-tocotrienol, a HMG CoA reductase inhibitor, on monocyte-endothelial cell adhesion. *J Nutr Sci Vitaminol (Tokyo).* 2002; 48:332–337. [PubMed: 12656204]
- Chen CW, Cheng HH. A rice bran oil diet increases LDL-receptor and HMG-CoA reductase mRNA expressions and insulin sensitivity in rats with streptozotocin/nicotinamide-induced type 2 diabetes. *J Nutr.* 2006; 136:1472–1476. [PubMed: 16702306]
- Chow CK, Draper HH. Isolation of gamma-tocotrienol dimers from *Hevea latex*. *Biochemistry.* 1970; 9:445–450. [PubMed: 5412669]
- Collins JJ, Evason K, Kornfeld K. Pharmacology of delayed aging and extended lifespan of *Caenorhabditis elegans*. *Exp Gerontol.* 2006
- Das S, Powell SR, Wang P, Divald A, Nesaretnam K, Tosaki A, Cordis GA, Maulik N, Das DK. Cardioprotection with palm tocotrienol: antioxidant activity of tocotrienol is linked with its ability to stabilize proteasomes. *Am J Physiol Heart Circ Physiol.* 2005; 289:H361–367. [PubMed: 15708953]
- Dietrich M, Traber MG, Jacques PF, Cross CE, Hu Y, Block G. Does {gamma}-Tocopherol Play a Role in the Primary Prevention of Heart Disease and Cancer? A Review. *J Am Coll Nutr.* 2006; 25:292–299. [PubMed: 16943450]
- Dringen R, Gutterer JM, Hirrlinger J. Glutathione metabolism in brain metabolic interaction between astrocytes and neurons in the defense against reactive oxygen species. *European Journal of Biochemistry.* 2000; 267:4912–4916. [PubMed: 10931173]
- Eitsuka T, Nakagawa K, Miyazawa T. Down-regulation of telomerase activity in DLD-1 human colorectal adenocarcinoma cells by tocotrienol. *Biochem Biophys Res Commun.* 2006
- Elson CE. Tropical oils: nutritional and scientific issues. *Critical Reviews in Food Science & Nutrition.* 1992; 31:79–102. [PubMed: 1345319]
- Elson CE, Qureshi AA. Coupling the cholesterol- and tumor-suppressive actions of palm oil to the impact of its minor constituents on 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. *Prostaglandins Leukotrienes & Essential Fatty Acids.* 1995; 52:205–207.
- Evans HM, Bishop KS. On the existence of a hitherto unrecognized dietary factor essential for reproduction. *Science.* 1922; 56:650–651. [PubMed: 17838496]
- Fairus S, Rosnah MN, Cheng HM, Sundram K. Metabolic fate of palm tocotrienols in human postprandial plasma model. *Asia Pac J Clin Nutr.* 2004; 13:S77.
- Friedrich MJ. To “E” or not to “E,” vitamin E’s role in health and disease is the question. *Jama.* 2004; 292:671–673. [PubMed: 15304447]

- Gao P, Morozowich W. Development of supersaturatable self-emulsifying drug delivery system formulations for improving the oral absorption of poorly soluble drugs. *Expert Opin Drug Deliv.* 2006; 3:97–110. [PubMed: 16370943]
- Garry PJ, Hunt WC, Bandrofchak JL, VanderJagt D, Goodwin JS. Vitamin A intake and plasma retinol levels in healthy elderly men and women. *Am J Clin Nutr.* 1987; 46:989–994. [PubMed: 3687828]
- Goh SH, Hew NF, Norhanom AW, Yadav M. Inhibition of tumour promotion by various palm-oil tocotrienols. *International Journal of Cancer.* 1994; 57:529–531.
- Gorman C. Vitamin E-gads. *Time.* 2005; 165:73.
- Gould MN, Haag JD, Kennan WS, Tanner MA, Elson CE. A comparison of tocopherol and tocotrienol for the chemoprevention of chemically induced rat mammary tumors. *American Journal of Clinical Nutrition.* 1991; 53:1068S–1070S. [PubMed: 1845366]
- Greenberg ER. Vitamin E supplements: good in theory, but is the theory good? *Ann Intern Med.* 2005; 142:75–76. [PubMed: 15579660]
- Grossman S, Waksman EG. New aspects of the inhibition of soybean lipoxygenase by alpha-tocopherol. Evidence for the existence of a specific complex. *International Journal of Biochemistry.* 1984; 16:281–289. [PubMed: 6421635]
- Gu J, Liu Y, Wen Y, Natarajan R, Lanting L, Nadler JL. Evidence that increased 12-lipoxygenase activity induces apoptosis in fibroblasts. *J Cell Physiol.* 2001; 186:357–365. [PubMed: 11169974]
- Gu JY, Wakizono Y, Sunada Y, Hung P, Nonaka M, Sugano M, Yamada K. Dietary effect of tocopherols and tocotrienols on the immune function of spleen and mesenteric lymph node lymphocytes in Brown Norway rats. *Bioscience, Biotechnology & Biochemistry.* 1999; 63:1697–1702.
- Guthrie N, Gapor A, Chambers AF, Carroll KK. Inhibition of proliferation of estrogen receptor-negative MDA-MB-435 and -positive MCF-7 human breast cancer cells by palm oil tocotrienols and tamoxifen, alone and in combination. *Journal of Nutrition.* 1997; 127:544S–548S. [PubMed: 9082043]
- Hagmann W, Kagawa D, Renaud C, Honn KV. Activity and protein distribution of 12-lipoxygenase in HEL cells: induction of membrane-association by phorbol ester TPA, modulation of activity by glutathione and 13-HPODE, and Ca(2+)-dependent translocation to membranes. *Prostaglandins.* 1993; 46:471–477. [PubMed: 8295977]
- Hall TJ, Schaeublin M, Missbach M. Evidence that c-src is involved in the process of osteoclastic bone resorption. *Biochem Biophys Res Commun.* 1994; 199:1237–1244. [PubMed: 8147865]
- Han D, Sen CK, Roy S, Kobayashi MS, Tritschler HJ, Packer L. Protection against glutamate-induced cytotoxicity in C6 glial cells by thiol antioxidants. *American Journal of Physiology.* 1997; 273:R1771–1778. [PubMed: 9374822]
- Har CH, Keong CK. Effects of tocotrienols on cell viability and apoptosis in normal murine liver cells (BNL CL.2) and liver cancer cells (BNL 1ME A.7R.1), in vitro. *Asia Pac J Clin Nutr.* 2005; 14:374–380. [PubMed: 16326644]
- Hathcock JN, Azzi A, Blumberg J, Bray T, Dickinson A, Frei B, Jialal I, Johnston CS, Kelly FJ, Kraemer K, Packer L, Parthasarathy S, Sies H, Traber MG. Vitamins E and C are safe across a broad range of intakes. *Am J Clin Nutr.* 2005; 81:736–745. [PubMed: 15817846]
- Hattori A, Fukushima T, Yoshimura H, Abe K, Imai K. Production of LLU-alpha following an oral administration of gamma-tocotrienol or gamma-tocopherol to rats. *Biol Pharm Bull.* 2000; 23:1395–1397. [PubMed: 11085376]
- Hayes KC, Pronczuk A, Liang JS. Differences in the plasma transport and tissue concentrations of tocopherols and tocotrienols: observations in humans and hamsters. *Proceedings of the Society for Experimental Biology & Medicine.* 1993; 202:353–359. [PubMed: 8437992]
- He L, Mo H, Hadisusilo S, Qureshi AA, Elson CE. Isoprenoids suppress the growth of murine B16 melanomas in vitro and in vivo. *Journal of Nutrition.* 1997; 127:668–674. [PubMed: 9164984]
- Hensley K, Benaksas EJ, Bolli R, Comp P, Grammas P, Hamdheydari L, Mou S, Pye QN, Stoddard MF, Wallis G, Williamson KS, West M, Wechter WJ, Floyd RA. New perspectives on vitamin E: gamma-tocopherol and carboxyethylhydroxychroman metabolites in biology and medicine. *Free Radic Biol Med.* 2004; 36:1–15. [PubMed: 14732286]
- Ho, D.; Yuen, KH.; Yap, SP. Drug delivery system: formulation for fat-soluble drugs. United States patent. 6,596,306. 2003.

- Hong JY, Kim JK, Song YK, Park JS, Kim CK. A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. *J Control Release*. 2006; 110:332–338. [PubMed: 16297483]
- Horvath G, Wessjohann L, Bigirimana J, Jansen M, Guisez Y, Caubergs R, Horemans N. Differential distribution of tocopherols and tocotrienols in photosynthetic and non-photosynthetic tissues. *Phytochemistry*. 2006; 67:1185–1195. [PubMed: 16777157]
- Hosomi A, Arita M, Sato Y, Kiyose C, Ueda T, Igarashi O, Arai H, Inoue K. Affinity for alpha-tocopherol transfer protein as a determinant of the biological activities of vitamin E analogs. *FEBS Letters*. 1997; 409:105–108. [PubMed: 9199513]
- Hsu CY, Persons PE, Spada AP, Bednar RA, Levitzki A, Zilberstein A. Kinetic analysis of the inhibition of the epidermal growth factor receptor tyrosine kinase by Lavendustin-A and its analogue. *J Biol Chem*. 1991; 266:21105–21112. [PubMed: 1939153]
- Ikeda I, Imasato Y, Sasaki E, Sugano M. Lymphatic transport of alpha-, gamma- and delta-tocotrienols and alpha-tocopherol in rats. *International Journal for Vitamin & Nutrition Research*. 1996; 66:217–221. [PubMed: 8899454]
- Ikeda S, Niwa T, Yamashita K. Selective uptake of dietary tocotrienols into rat skin. *J Nutr Sci Vitaminol (Tokyo)*. 2000; 46:141–143. [PubMed: 10955281]
- Ikeda S, Tohyama T, Yoshimura H, Hamamura K, Abe K, Yamashita K. Dietary alpha-tocopherol decreases alpha-tocotrienol but not gamma-tocotrienol concentration in rats. *J Nutr*. 2003; 133:428–434. [PubMed: 12566479]
- Ikeda S, Toyoshima K, Yamashita K. Dietary sesame seeds elevate alpha- and gamma-tocotrienol concentrations in skin and adipose tissue of rats fed the tocotrienol-rich fraction extracted from palm oil. *J Nutr*. 2001; 131:2892–2897. [PubMed: 11694614]
- Ima-Nirwana S, Suhaniza S. Effects of tocopherols and tocotrienols on body composition and bone calcium content in adrenalectomized rats replaced with dexamethasone. *J Med Food*. 2004; 7:45–51. [PubMed: 15117552]
- Ingraham CA, Cox ME, Ward DC, Fults DW, Maness PF. c-src and other proto-oncogenes implicated in neuronal differentiation. *Mol Chem Neuropathol*. 1989; 10:1–14. [PubMed: 2472150]
- Inokuchi H, Hirokane H, Tsuzuki T, Nakagawa K, Igarashi M, Miyazawa T. Anti-angiogenic activity of tocotrienol. *Biosci Biotechnol Biochem*. 2003; 67:1623–1627. [PubMed: 12913317]
- Iqbal J, Minhajuddin M, Beg ZH. Suppression of 7,12-dimethylbenz[alpha]anthracene-induced carcinogenesis and hypercholesterolaemia in rats by tocotrienol-rich fraction isolated from rice bran oil. *Eur J Cancer Prev*. 2003; 12:447–453. [PubMed: 14639121]
- Iqbal J, Minhajuddin M, Beg ZH. Suppression of diethylnitrosamine and 2-acetylaminofluorene-induced hepatocarcinogenesis in rats by tocotrienol-rich fraction isolated from rice bran oil. *Eur J Cancer Prev*. 2004; 13:515–520. [PubMed: 15548946]
- Ishizaki Y, Murota S. Arachidonic acid metabolism in cultured astrocytes: presence of 12-lipoxygenase activity in the intact cells. *Neurosci Lett*. 1991; 131:149–152. [PubMed: 1762689]
- Ishizawa R, Parsons SJ. c-Src and cooperating partners in human cancer. *Cancer Cell*. 2004; 6:209–214. [PubMed: 15380511]
- Jishage K, Arita M, Igarashi K, Iwata T, Watanabe M, Ogawa M, Ueda O, Kamada N, Inoue K, Arai H, Suzuki H. Alpha-tocopherol transfer protein is important for the normal development of placental labyrinthine trophoblasts in mice. *Journal of Biological Chemistry*. 2001; 276:1669–1672. [PubMed: 11076932]
- Johnson NL, Gardner AM, Diener KM, Lange-Carter CA, Gleavy J, Jarpe MB, Minden A, Karin M, Zon LI, Johnson GL. Signal transduction pathways regulated by mitogen-activated/extracellular response kinase kinase kinase induce cell death. *J Biol Chem*. 1996; 271:3229–3237. [PubMed: 8621725]
- Kaempf-Rotzoll DE, Traber MG, Arai H. Vitamin E and transfer proteins. *Current Opinion in Lipidology*. 2003; 14:249–254. [PubMed: 12840655]
- Kagan VE, Serbinova EA, Forte T, Scita G, Packer L. Recycling of vitamin E in human low density lipoproteins. *Journal of Lipid Research*. 1992; 33:385–397. [PubMed: 1314881]
- Kaku S, Yunoki S, Mori M, Ohkura K, Nonaka M, Sugano M, Yamada K. Effect of dietary antioxidants on serum lipid contents and immunoglobulin productivity of lymphocytes in Sprague-Dawley rats. *Bioscience, Biotechnology & Biochemistry*. 1999; 63:575–576.

- Kamat JP, Devasagayam TP. Tocotrienols from palm oil as potent inhibitors of lipid peroxidation and protein oxidation in rat brain mitochondria. *Neuroscience Letters*. 1995; 195:179–182. [PubMed: 8584204]
- Kanaya Y, Doi T, Sasaki H, Fujita A, Matsuno S, Okamoto K, Nakano Y, Tsujiwaki S, Furuta H, Nishi M, Tsuno T, Taniguchi H, Nanjo K. Rice bran extract prevents the elevation of plasma peroxy lipid in KKAY diabetic mice. *Diabetes Res Clin Pract*. 2004; 66(Suppl 1):S157–160. [PubMed: 15563968]
- Khanna S, Patel V, Rink C, Roy S, Sen CK. Delivery of orally supplemented alpha-tocotrienol to vital organs of rats and tocopherol-transport protein deficient mice. *Free Radic Biol Med*. 2005a; 39:1310–1319. [PubMed: 16257640]
- Khanna S, Roy S, Parinandi NL, Maurer M, Sen CK. Characterization of the potent neuroprotective properties of the natural vitamin E alpha-tocotrienol. *J Neurochem*. 2006 in press.
- Khanna S, Roy S, Ryu H, Bahadduri P, Swaan PW, Ratan RR, Sen CK. Molecular basis of vitamin E action: tocotrienol modulates 12-lipoxygenase, a key mediator of glutamate-induced neurodegeneration. *J Biol Chem*. 2003; 278:43508–43515. [PubMed: 12917400]
- Khanna S, Roy S, Slivka A, Craft TK, Chaki S, Rink C, Notestine MA, DeVries AC, Parinandi NL, Sen CK. Neuroprotective properties of the natural vitamin E alpha-tocotrienol. *Stroke*. 2005b; 36:2258–2264. [PubMed: 16166580]
- Khanna S, Venojarvi M, Roy S, Sen CK. Glutamate-induced c-Src activation in neuronal cells. *Methods Enzymol*. 2002; 352:191–198. [PubMed: 12125347]
- Khosla P, Patel V, Whinter JM, Khanna S, Rakhkovskaya M, Roy S, Sen CK. Postprandial levels of the natural vitamin e tocotrienol in human circulation. *Antioxid Redox Signal*. 2006; 8:1059–1068. [PubMed: 16771695]
- Kitagawa K, Matsumoto M, Hori M. Cerebral ischemia in 5-lipoxygenase knockout mice. *Brain Res*. 2004; 1004:198–202. [PubMed: 15033436]
- Kluth D, Landes N, Pfluger P, Muller-Schmehl K, Weiss K, Bumke-Vogt C, Ristow M, Brigelius-Flohe R. Modulation of Cyp3a11 mRNA expression by alpha-tocopherol but not gamma-tocotrienol in mice. *Free Radic Biol Med*. 2005; 38:507–514. [PubMed: 15649653]
- Koba K, Abe K, Ikeda I, Sugano M. Effects of alpha-tocopherol and tocotrienols on blood pressure and linoleic acid metabolism in the spontaneously hypertensive rat (SHR). *Bioscience, Biotechnology & Biochemistry*. 1992; 56:1420–1423.
- Komiyama K, Iizuka K, Yamaoka M, Watanabe H, Tsuchiya N, Umezawa I. Studies on the biological activity of tocotrienols. *Chemical & Pharmaceutical Bulletin*. 1989; 37:1369–1371.
- Kumar KS, Raghavan M, Hieber K, Ege C, Mog S, Parra N, Hildabrand A, Singh V, Srinivasan V, Toles R, Karikari P, Petrovics G, Seed T, Srivastava S, Papas A. Preferential radiation sensitization of prostate cancer in nude mice by nutraceutical antioxidant gamma-tocotrienol. *Life Sci*. 2006; 78:2099–2104. [PubMed: 16413038]
- Kwon KJ, Jung YS, Lee SH, Moon CH, Baik EJ. Arachidonic acid induces neuronal death through lipoxygenase and cytochrome P450 rather than cyclooxygenase. *J Neurosci Res*. 2005; 81:73–84. [PubMed: 15931672]
- Landes N, Pfluger P, Kluth D, Birringer M, Ruhl R, Bol GF, Glatt H, Brigelius-Flohe R. Vitamin E activates gene expression via the pregnane X receptor. *Biochem Pharmacol*. 2003; 65:269–273. [PubMed: 12504802]
- Lau AF. c-Src: bridging the gap between phosphorylation- and acidification-induced gap junction channel closure. *Sci STKE*. 2005; 2005:e33.
- Lebeau A, Esclaire F, Rostene W, Pelaprat D. Baicalein protects cortical neurons from beta-amyloid (25-35) induced toxicity. *Neuroreport*. 2001; 12:2199–2202. [PubMed: 11447334]
- Lee JR, Koretzky GA. Extracellular signal-regulated kinase-2, but not c-Jun NH2-terminal kinase, activation correlates with surface IgM-mediated apoptosis in the WEHI 231 B cell line. *J Immunol*. 1998; 161:1637–1644. [PubMed: 9712025]
- Lenmyr F, Ericsson A, Gerwins P, Akterin S, Ahlstrom H, Terent A. Src family kinase-inhibitor PP2 reduces focal ischemic brain injury. *Acta Neurol Scand*. 2004; 110:175–179. [PubMed: 15285775]
- Leonard SW, Paterson E, Atkinson JK, Ramakrishnan R, Cross CE, Traber MG. Studies in humans using deuterium-labeled alpha- and gamma-tocopherols demonstrate faster plasma gamma-tocopherol

- disappearance and greater gamma-metabolite production. *Free Radic Biol Med.* 2005; 38:857–866. [PubMed: 15749381]
- Lepley RA, Muskardin DT, Fitzpatrick FA. Tyrosine kinase activity modulates catalysis and translocation of cellular 5-lipoxygenase. *Journal of Biological Chemistry.* 1996; 271:6179–6184. [PubMed: 8626407]
- Li Y, Maher P, Schubert D. A role for 12-lipoxygenase in nerve cell death caused by glutathione depletion. *Neuron.* 1997; 19:453–463. [PubMed: 9292733]
- Lodge JK, Hall WL, Jeanes YM, Protegente AR. Physiological factors influencing vitamin E biokinetics. *Ann N Y Acad Sci.* 2004; 1031:60–73. [PubMed: 15753134]
- Lodge JK, Ridlington J, Leonard S, Vaule H, Traber MG. Alpha- and gamma-tocotrienols are metabolized to carboxyethyl-hydroxychroman derivatives and excreted in human urine. *Lipids.* 2001; 36:43–48. [PubMed: 11214728]
- Maness PF, Aubry M, Shores CG, Frame L, Pfenninger KH. c-src gene product in developing rat brain is enriched in nerve growth cone membranes. *Proc Natl Acad Sci U S A.* 1988; 85:5001–5005. [PubMed: 2455889]
- Mazlan M, Sue Mian T, Mat Top G, Zurinah Wan Ngah W. Comparative effects of alpha-tocopherol and gamma-tocotrienol against hydrogen peroxide induced apoptosis on primary-cultured astrocytes. *J Neurol Sci.* 2006; 243:5–12. [PubMed: 16442562]
- McIntyre BS, Briski KP, Gapor A, Sylvester PW. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on preneoplastic and neoplastic mouse mammary epithelial cells. *Proc Soc Exp Biol Med.* 2000a; 224:292–301. [PubMed: 10964265]
- McIntyre BS, Briski KP, Tirmenstein MA, Fariss MW, Gapor A, Sylvester PW. Antiproliferative and apoptotic effects of tocopherols and tocotrienols on normal mouse mammary epithelial cells. *Lipids.* 2000b; 35:171–180. [PubMed: 10757548]
- Mensink RP, van Houwelingen AC, Kromhout D, Hornstra G. A vitamin E concentrate rich in tocotrienols had no effect on serum lipids, lipoproteins, or platelet function in men with mildly elevated serum lipid concentrations. *American Journal of Clinical Nutrition.* 1999; 69:213–219. [PubMed: 9989682]
- Meyenberg A, Goldblum D, Zingg JM, Azzi A, Nesaretnam K, Kilchenmann M, Frueh BE. Tocotrienol inhibits proliferation of human Tenon's fibroblasts in vitro: a comparative study with vitamin E forms and mitomycin C. *Graefes Arch Clin Exp Ophthalmol.* 2005; 243:1263–1271. [PubMed: 15909162]
- Miller ER 3rd, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. *Ann Intern Med.* 2005; 142:37–46. [PubMed: 15537682]
- Minhajuddin M, Beg ZH, Iqbal J. Hypolipidemic and antioxidant properties of tocotrienol rich fraction isolated from rice bran oil in experimentally induced hyperlipidemic rats. *Food Chem Toxicol.* 2005; 43:747–753. [PubMed: 15778015]
- Mishima K, Tanaka T, Pu F, Egashira N, Iwasaki K, Hidaka R, Matsunaga K, Takata J, Karube Y, Fujiwara M. Vitamin E isoforms alpha-tocotrienol and gamma-tocopherol prevent cerebral infarction in mice. *Neurosci Lett.* 2003; 337:56–60. [PubMed: 12524170]
- Miyamoto T, Lindgren JA, Hokfelt T, Samuelsson B. Formation of lipoxygenase products in the rat brain. *Adv Prostaglandin Thromboxane Leukot Res.* 1987a; 17B:929–933. [PubMed: 2823580]
- Miyamoto T, Lindgren JA, Hokfelt T, Samuelsson B. Regional distribution of leukotriene and monohydroxyeicosatetraenoic acid production in the rat brain. Highest leukotriene C4 formation in the hypothalamus. *FEBS Lett.* 1987b; 216:123–127. [PubMed: 3034669]
- Miyazawa T, Inokuchi H, Hirokane H, Tsuzuki T, Nakagawa K, Igarashi M. Anti-angiogenic potential of tocotrienol in vitro. *Biochemistry (Mosc).* 2004; 69:67–69. [PubMed: 14972020]
- Mizushima Y, Nakagawa K, Shibata A, Awata Y, Kuriyama I, Shimazaki N, Koiwai O, Uchiyama Y, Sakaguchi K, Miyazawa T, Yoshida H. Inhibitory effect of tocotrienol on eukaryotic DNA polymerase lambda and angiogenesis. *Biochem Biophys Res Commun.* 2006; 339:949–955. [PubMed: 16325764]
- Mo H, Elson CE. Apoptosis and cell-cycle arrest in human and murine tumor cells are initiated by isoprenoids. *Journal of Nutrition.* 1999; 129:804–813. [PubMed: 10203554]

- Musiek ES, Breeding RS, Milne GL, Zanoni G, Morrow JD, McLaughlin B. Cyclopentenone isoprostanes are novel bioactive products of lipid oxidation which enhance neurodegeneration. *J Neurochem*. 2006; 97:1301–1313. [PubMed: 16638022]
- Nafeeza MI, Fauzee AM, Kamsiah J, Gapor MT. Comparative effects of a tocotrienol-rich fraction and tocopherol in aspirin-induced gastric lesions in rats. *Asia Pac J Clin Nutr*. 2002; 11:309–313. [PubMed: 12495264]
- Nafeeza MI, Kang TT. Synergistic effects of tocopherol, tocotrienol, and ubiquinone in indomethacin-induced experimental gastric lesions. *Int J Vitam Nutr Res*. 2005; 75:149–155. [PubMed: 15929636]
- Naguib Y, Hari SP, Passwater R Jr, Huang D. Antioxidant activities of natural vitamin E formulations. *J Nutr Sci Vitaminol (Tokyo)*. 2003; 49:217–220. [PubMed: 14598906]
- Naito Y, Shimozawa M, Kuroda M, Nakabe N, Manabe H, Katada K, Kokura S, Ichikawa H, Yoshida N, Noguchi N, Yoshikawa T. Tocotrienols reduce 25-hydroxycholesterol-induced monocyte-endothelial cell interaction by inhibiting the surface expression of adhesion molecules. *Atherosclerosis*. 2005; 180:19–25. [PubMed: 15823271]
- Nakagawa K, Eitsuka T, Inokuchi H, Miyazawa T. DNA chip analysis of comprehensive food function: Inhibition of angiogenesis and telomerase activity with unsaturated vitamin E, tocotrienol. *Biofactors*. 2004; 21:5–10. [PubMed: 15630161]
- Nesaretnam K, Ambra R, Selvaduray KR, Radhakrishnan A, Reimann K, Razak G, Virgili F. Tocotrienol-rich fraction from palm oil affects gene expression in tumors resulting from MCF-7 cell inoculation in athymic mice. *Lipids*. 2004; 39:459–467. [PubMed: 15506241]
- Nesaretnam K, Dorasamy S, Darbre PD. Tocotrienols inhibit growth of ZR-75-1 breast cancer cells. *Int J Food Sci Nutr*. 2000; 51(Suppl):S95–103. [PubMed: 11271861]
- Nesaretnam K, Guthrie N, Chambers AF, Carroll KK. Effect of tocotrienols on the growth of a human breast cancer cell line in culture. *Lipids*. 1995; 30:1139–1143. [PubMed: 8614304]
- Nesaretnam K, Stephen R, Dils R, Darbre P. Tocotrienols inhibit the growth of human breast cancer cells irrespective of estrogen receptor status. *Lipids*. 1998; 33:461–469. [PubMed: 9625593]
- Newaz MA, Nawal NN. Effect of gamma-tocotrienol on blood pressure, lipid peroxidation and total antioxidant status in spontaneously hypertensive rats (SHR). *Clinical & Experimental Hypertension (New York)*. 1999; 21:1297–1313.
- Newaz MA, Yousefipour Z, Nawal N, Adeeb N. Nitric oxide synthase activity in blood vessels of spontaneously hypertensive rats: antioxidant protection by gamma-tocotrienol. *J Physiol Pharmacol*. 2003; 54:319–327. [PubMed: 14566071]
- Ngh WZ, Jarien Z, San MM, Marzuki A, Top GM, Shamaan NA, Kadir KA. Effect of tocotrienols on hepatocarcinogenesis induced by 2-acetylaminofluorene in rats. *American Journal of Clinical Nutrition*. 1991; 53:1076S–1081S. [PubMed: 1672785]
- Nishiyama M, Okamoto H, Watanabe T, Hori T, Hada T, Ueda N, Yamamoto S, Tsukamoto H, Watanabe K, Kirino T. Localization of arachidonate 12-lipoxygenase in canine brain tissues. *Journal of Neurochemistry*. 1992; 58:1395–1400. [PubMed: 1548473]
- Nishiyama M, Watanabe T, Ueda N, Tsukamoto H, Watanabe K. Arachidonate 12-lipoxygenase is localized in neurons, glial cells, and endothelial cells of the canine brain. *Journal of Histochemistry & Cytochemistry*. 1993; 41:111–117. [PubMed: 8417106]
- Noguchi N, Hanyu R, Nonaka A, Okimoto Y, Kodama T. Inhibition of THP-1 cell adhesion to endothelial cells by alpha-tocopherol and alpha-tocotrienol is dependent on intracellular concentration of the antioxidants. *Free Radic Biol Med*. 2003; 34:1614–1620. [PubMed: 12788481]
- Norazlina M, Ima-Nirwana S, Abul Gapor MT, Abdul Kadir Khalid B. Tocotrienols are needed for normal bone calcification in growing female rats. *Asia Pac J Clin Nutr*. 2002; 11:194–199. [PubMed: 12230232]
- Numakawa Y, Numakawa T, Matsumoto T, Yagasaki Y, Kumamaru E, Kunugi H, Taguchi T, Niki E. Vitamin E protected cultured cortical neurons from oxidative stress-induced cell death through the activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. *J Neurochem*. 2006; 97:1191–1202. [PubMed: 16686696]
- O'Byrne D, Grundy S, Packer L, Devaraj S, Baldenius K, Hoppe PP, Kraemer K, Jialal I, Traber MG. Studies of LDL oxidation following alpha-, gamma-, or delta-tocotrienyl acetate supplementation

- of hypercholesterolemic humans. *Free Radical Biology & Medicine*. 2000; 29:834–845. [PubMed: 11063909]
- Okabe M, Oji M, Ikeda I, Tachibana H, Yamada K. Tocotrienol levels in various tissues of Sprague-Dawley rats after intragastric administration of tocotrienols. *Biosci Biotechnol Biochem*. 2002; 66:1768–1771. [PubMed: 12353645]
- Osakada F, Hashino A, Kume T, Katsuki H, Kaneko S, Akaike A. Alpha-tocotrienol provides the most potent neuroprotection among vitamin E analogs on cultured striatal neurons. *Neuropharmacology*. 2004; 47:904–915. [PubMed: 15527824]
- Palozza P, Verdecchia S, Avanzi L, Vertuani S, Serini S, Iannone A, Manfredini S. Comparative antioxidant activity of tocotrienols and the novel chromanyl-polyisoprenyl molecule FeAox-6 in isolated membranes and intact cells. *Mol Cell Biochem*. 2006; 287:21–32. [PubMed: 16645729]
- Panfili G, Fratianni A, Irano M. Normal phase high-performance liquid chromatography method for the determination of tocopherols and tocotrienols in cereals. *J Agric Food Chem*. 2003; 51:3940–3944. [PubMed: 12822927]
- Parker RA, Pearce BC, Clark RW, Gordon DA, Wright JJ. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. *Journal of Biological Chemistry*. 1993; 268:11230–11238. [PubMed: 8388388]
- Paul R, Zhang ZG, Eliceiri BP, Jiang Q, Boccia AD, Zhang RL, Chopp M, Cheresch DA. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke. *Nat Med*. 2001; 7:222–227. [PubMed: 11175854]
- Pearce BC, Parker RA, Deason ME, Dischino DD, Gillespie E, Qureshi AA, Volk K, Wright JJ. Inhibitors of cholesterol biosynthesis. 2. Hypocholesterolemic and antioxidant activities of benzopyran and tetrahydronaphthalene analogues of the tocotrienols. *Journal of Medicinal Chemistry*. 1994; 37:526–541. [PubMed: 8120870]
- Pearce BC, Parker RA, Deason ME, Qureshi AA, Wright JJ. Hypocholesterolemic activity of synthetic and natural tocotrienols. *Journal of Medicinal Chemistry*. 1992; 35:3595–3606. [PubMed: 1433170]
- Podda M, Weber C, Traber MG, Packer L. Simultaneous determination of tissue tocopherols, tocotrienols, ubiquinol, and ubiquinones. *Journal of Lipid Research*. 1996; 37:893–901. [PubMed: 8732789]
- Porfirova S, Bergmuller E, Tropf S, Lemke R, Dormann P. Isolation of an Arabidopsis mutant lacking vitamin E and identification of a cyclase essential for all tocopherol biosynthesis. *Proc Natl Acad Sci U S A*. 2002; 99:12495–12500. [PubMed: 12213958]
- Pyper JM, Bolen JB. Neuron-specific splicing of C-SRC RNA in human brain. *J Neurosci Res*. 1989; 24:89–96. [PubMed: 2681803]
- Qureshi AA, Bradlow BA, Brace L, Manganello J, Peterson DM, Pearce BC, Wright JJ, Gapor A, Elson CE. Response of hypercholesterolemic subjects to administration of tocotrienols. *Lipids*. 1995; 30:1171–1177. [PubMed: 8614309]
- Qureshi AA, Burger WC, Peterson DM, Elson CE. The structure of an inhibitor of cholesterol biosynthesis isolated from barley. *Journal of Biological Chemistry*. 1986; 261:10544–10550. [PubMed: 3733719]
- Qureshi AA, Mo H, Packer L, Peterson DM. Isolation and identification of novel tocotrienols from rice bran with hypocholesterolemic, antioxidant, and antitumor properties. *Journal of Agricultural & Food Chemistry*. 2000; 48:3130–3140. [PubMed: 10956081]
- Qureshi AA, Peterson DM. The combined effects of novel tocotrienols and lovastatin on lipid metabolism in chickens. *Atherosclerosis*. 2001; 156:39–47. [PubMed: 11368995]
- Qureshi AA, Peterson DM, Hasler-Rapacz JO, Rapacz J. Novel tocotrienols of rice bran suppress cholesterol synthesis in hereditary hypercholesterolemic swine. *J Nutr*. 2001a; 131:223–230. [PubMed: 11160537]
- Qureshi AA, Qureshi N, Hasler-Rapacz JO, Weber FE, Chaudhary V, Crenshaw TD, Gapor A, Ong AS, Chong YH, Peterson D. Dietary tocotrienols reduce concentrations of plasma cholesterol, apolipoprotein B, thromboxane B2, and platelet factor 4 in pigs with inherited hyperlipidemias. *American Journal of Clinical Nutrition*. 1991a; 53:1042S–1046S. [PubMed: 2012015]
- Qureshi AA, Qureshi N, Wright JJ, Shen Z, Kramer G, Gapor A, Chong YH, DeWitt G, Ong A, Peterson DM. Lowering of serum cholesterol in hypercholesterolemic humans by tocotrienols (palmvitee). *American Journal of Clinical Nutrition*. 1991b; 53:1021S–1026S. [PubMed: 2012010]

- Qureshi AA, Salser WA, Parmar R, Emeson EE. Novel tocotrienols of rice bran inhibit atherosclerotic lesions in C57BL/6 ApoE-deficient mice. *J Nutr*. 2001b; 131:2606–2618. [PubMed: 11584079]
- Qureshi AA, Sami SA, Salser WA, Khan FA. Synergistic effect of tocotrienol-rich fraction (TRF(25)) of rice bran and lovastatin on lipid parameters in hypercholesterolemic humans. *J Nutr Biochem*. 2001c; 12:318–329. [PubMed: 11516635]
- Qureshi AA, Sami SA, Salser WA, Khan FA. Dose-dependent suppression of serum cholesterol by tocotrienol-rich fraction (TRF25) of rice bran in hypercholesterolemic humans. *Atherosclerosis*. 2002; 161:199–207. [PubMed: 11882333]
- Raederstorff D, Elste V, Aebischer C, Weber P. Effect of either gamma-tocotrienol or a tocotrienol mixture on the plasma lipid profile in hamsters. *Ann Nutr Metab*. 2002; 46:17–23. [PubMed: 11914511]
- Rahmat A, Ngah WZ, Shamaan NA, Gapor A, Abdul Kadir K. Long-term administration of tocotrienols and tumor-marker enzyme activities during hepatocarcinogenesis in rats. *Nutrition*. 1993; 9:229–232. [PubMed: 8102564]
- Reddanna P, Rao MK, Reddy CC. Inhibition of 5-lipoxygenase by vitamin E. *FEBS Letters*. 1985; 193:39–43. [PubMed: 3934003]
- Rippert P, Scimemi C, Dubald M, Matringe M. Engineering plant shikimate pathway for production of tocotrienol and improving herbicide resistance. *Plant Physiol*. 2004; 134:92–100. [PubMed: 14684842]
- Roy S, Lado BH, Khanna S, Sen CK. Vitamin E sensitive genes in the developing rat fetal brain: a high-density oligonucleotide microarray analysis. *FEBS Lett*. 2002; 530:17–23. [PubMed: 12387859]
- Saito H, Kiyose C, Yoshimura H, Ueda T, Kondo K, Igarashi O. Gamma-tocotrienol, a vitamin E homolog, is a natriuretic hormone precursor. *J Lipid Res*. 2003; 44:1530–1535. [PubMed: 12730299]
- Sakai M, Okabe M, Tachibana H, Yamada K. Apoptosis induction by gamma-tocotrienol in human hepatoma Hep3B cells. *J Nutr Biochem*. 2005
- Sakai M, Okabe M, Yamasaki M, Tachibana H, Yamada K. Induction of apoptosis by tocotrienol in rat hepatoma dRLh-84 cells. *Anticancer Res*. 2004; 24:1683–1688. [PubMed: 15274341]
- Schroeder MT, Becker EM, Skibsted LH. Molecular mechanism of antioxidant synergism of tocotrienols and carotenoids in palm oil. *J Agric Food Chem*. 2006; 54:3445–3453. [PubMed: 16637706]
- Schubert D, Piasecki D. Oxidative glutamate toxicity can be a component of the excitotoxicity cascade. *Journal of Neuroscience*. 2001; 21:7455–7462. [PubMed: 11567035]
- Schulz JB, Lindenau J, Seyfried J, Dichgans J. Glutathione, oxidative stress and neurodegeneration. *European Journal of Biochemistry*. 2000; 267:4904–4911. [PubMed: 10931172]
- Schwarz K. Role of vitamin E, selenium, and related factors in experimental nutritional liver disease. *Federation Proc*. 1965; 24:58–67. [PubMed: 14279002]
- Schwedhelm E, Maas R, Troost R, Boger RH. Clinical pharmacokinetics of antioxidants and their impact on systemic oxidative stress. *Clin Pharmacokinet*. 2003; 42:437–459. [PubMed: 12739983]
- Sen CK, Khanna S, Roy S. Tocotrienol: the natural vitamin E to defend the nervous system? *Ann N Y Acad Sci*. 2004; 1031:127–142. [PubMed: 15753140]
- Sen CK, Khanna S, Roy S. Tocotrienols: Vitamin E beyond tocopherols. *Life Sci*. 2006; 78:2088–2098. [PubMed: 16458936]
- Sen CK, Khanna S, Roy S, Packer L. Molecular basis of vitamin E action. Tocotrienol potently inhibits glutamate-induced pp60(c-Src) kinase activation and death of HT4 neuronal cells. *Journal of Biological Chemistry*. 2000; 275:13049–13055. [PubMed: 10777609]
- Serbinova E, Kagan V, Han D, Packer L. Free radical recycling and intramembrane mobility in the antioxidant properties of alpha-tocopherol and alpha-tocotrienol. *Free Radical Biology & Medicine*. 1991; 10:263–275. [PubMed: 1649783]
- Serbinova EA, Packer L. Antioxidant properties of alpha-tocopherol and alpha-tocotrienol. *Methods in Enzymology*. 1994; 234:354–366. [PubMed: 7808307]
- Sever N, Song BL, Yabe D, Goldstein JL, Brown MS, DeBose-Boyd RA. Insig-dependent ubiquitination and degradation of mammalian 3-hydroxy-3-methylglutaryl-CoA reductase stimulated by sterols and geranylgeraniol. *J Biol Chem*. 2003; 278:52479–52490. [PubMed: 14563840]

- Shah S, Gapor A, Sylvester PW. Role of caspase-8 activation in mediating vitamin E-induced apoptosis in murine mammary cancer cells. *Nutr Cancer*. 2003; 45:236–246. [PubMed: 12881019]
- Shah S, Sylvester PW. Tocotrienol-induced caspase-8 activation is unrelated to death receptor apoptotic signaling in neoplastic mammary epithelial cells. *Exp Biol Med (Maywood)*. 2004; 229:745–755. [PubMed: 15337828]
- Shah SJ, Sylvester PW. Gamma-tocotrienol inhibits neoplastic mammary epithelial cell proliferation by decreasing Akt and nuclear factor kappaB activity. *Exp Biol Med (Maywood)*. 2005a; 230:235–241. [PubMed: 15792944]
- Shah SJ, Sylvester PW. Tocotrienol-induced cytotoxicity is unrelated to mitochondrial stress apoptotic signaling in neoplastic mammary epithelial cells. *Biochem Cell Biol*. 2005b; 83:86–95. [PubMed: 15746970]
- Shay JW, Wright WE. Telomerase therapeutics for cancer: challenges and new directions. *Nat Rev Drug Discov*. 2006; 5:577–584. [PubMed: 16773071]
- Shohami E, Glantz L, Nates J, Feuerstein G. The mixed lipoxygenase/cyclooxygenase inhibitor SK&F 105809 reduces cerebral edema after closed head injury in rat. *J Basic Clin Physiol Pharmacol*. 1992; 3:99–107. [PubMed: 1295574]
- Shun MC, Yu W, Gapor A, Parsons R, Atkinson J, Sanders BG, Kline K. Pro-apoptotic mechanisms of action of a novel vitamin E analog (alpha-TEA) and a naturally occurring form of vitamin E (delta-tocotrienol) in MDA-MB-435 human breast cancer cells. *Nutr Cancer*. 2004; 48:95–105. [PubMed: 15203383]
- Shupnik MA. Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. *Oncogene*. 2004; 23:7979–7989. [PubMed: 15489915]
- Soelaiman IN, Ahmad NS, Khalid BA. Palm oil tocotrienol mixture is better than alpha-tocopherol acetate in protecting bones against free-radical induced elevation of bone-resorbing cytokines. *Asia Pac J Clin Nutr*. 2004; 13:S111.
- Solomons NW, Orozco M. Alleviation of vitamin A deficiency with palm fruit and its products. *Asia Pac J Clin Nutr*. 2003; 12:373–384. [PubMed: 14506004]
- Song BL, Debose-Boyd RA. Insig-dependent ubiquitination and degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase stimulated by delta - and gamma -tocotrienols. *J Biol Chem*. 2006
- Sonnen AF, Bakirci H, Netscher T, Nau WM. Effect of temperature, cholesterol content, and antioxidant structure on the mobility of vitamin E constituents in biomembrane models studied by laterally diffusion-controlled fluorescence quenching. *J Am Chem Soc*. 2005; 127:15575–15584. [PubMed: 16262423]
- Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. *Cell*. 1991; 64:693–702. [PubMed: 1997203]
- Srivastava JK, Gupta S. Tocotrienol-rich fraction of palm oil induces cell cycle arrest and apoptosis selectively in human prostate cancer cells. *Biochem Biophys Res Commun*. 2006; 346:447–453. [PubMed: 16762318]
- Steiner M. Vitamin E: more than an antioxidant. *Clin Cardiol*. 1993; 16:116–18. [PubMed: 8472393]
- Suarna C, Hood RL, Dean RT, Stocker R. Comparative antioxidant activity of tocotrienols and other natural lipid-soluble antioxidants in a homogeneous system, and in rat and human lipoproteins. *Biochimica et Biophysica Acta*. 1993; 1166:163–170. [PubMed: 8443232]
- Sugano M, Koba K, Tsuji E. Health benefits of rice bran oil. *Anticancer Research*. 1999; 19:3651–3657. [PubMed: 10625933]
- Sun X, Shih AY, Johannssen HC, Erb H, Li P, Murphy TH. Two-photon Imaging of Glutathione Levels in Intact Brain Indicates Enhanced Redox Buffering in Developing Neurons and Cells at the Cerebrospinal Fluid and Blood-Brain Interface. *J Biol Chem*. 2006; 281:17420–17431. [PubMed: 16624809]
- Sundram K, Khor HT, Ong AS, Pathmanathan R. Effect of dietary palm oils on mammary carcinogenesis in female rats induced by 7,12-dimethylbenz(a)anthracene. *Cancer Research*. 1989; 49:1447–1451. [PubMed: 2493981]
- Sundram K, Sambanthamurthi R, Tan YA. Palm fruit chemistry and nutrition. *Asia Pac J Clin Nutr*. 2003; 12:355–362. [PubMed: 14506001]

- Suzuki YJ, Tsuchiya M, Wassall SR, Choo YM, Govil G, Kagan VE, Packer L. Structural and dynamic membrane properties of alpha-tocopherol and alpha-tocotrienol: implication to the molecular mechanism of their antioxidant potency. *Biochemistry*. 1993; 32:10692–10699. [PubMed: 8399214]
- Sylvester PW, McIntyre BS, Gapor A, Briski KP. Vitamin E inhibition of normal mammary epithelial cell growth is associated with a reduction in protein kinase C(alpha) activation. *Cell Prolif*. 2001; 34:347–357. [PubMed: 11736999]
- Sylvester PW, Nachnani A, Shah S, Briski KP. Role of GTP-binding proteins in reversing the antiproliferative effects of tocotrienols in preneoplastic mammary epithelial cells. *Asia Pac J Clin Nutr*. 2002; 11(Suppl 7):S452–459. [PubMed: 12492634]
- Sylvester PW, Shah S. Intracellular mechanisms mediating tocotrienol-induced apoptosis in neoplastic mammary epithelial cells. *Asia Pac J Clin Nutr*. 2005a; 14:366–373. [PubMed: 16326643]
- Sylvester PW, Shah SJ. Mechanisms mediating the antiproliferative and apoptotic effects of vitamin E in mammary cancer cells. *Front Biosci*. 2005b; 10:699–709. [PubMed: 15569611]
- Sylvester PW, Shah SJ, Samant GV. Intracellular signaling mechanisms mediating the antiproliferative and apoptotic effects of gamma-tocotrienol in neoplastic mammary epithelial cells. *J Plant Physiol*. 2005; 162:803–810. [PubMed: 16008108]
- Takahashi K, Loo G. Disruption of mitochondria during tocotrienol-induced apoptosis in MDA-MB-231 human breast cancer cells. *Biochem Pharmacol*. 2004; 67:315–324. [PubMed: 14698044]
- Tan DT, Khor HT, Low WH, Ali A, Gapor A. Effect of a palm-oil-vitamin E concentrate on the serum and lipoprotein lipids in humans. *American Journal of Clinical Nutrition*. 1991; 53:1027S–1030S. [PubMed: 2012011]
- Tan S, Schubert D, Maher P. Oxytosis: A novel form of programmed cell death. *Current Topics in Medicinal Chemistry*. 2001; 1:497–506. [PubMed: 11895126]
- Tanito M, Itoh N, Yoshida Y, Hayakawa M, Ohira A, Niki E. Distribution of tocopherols and tocotrienols to rat ocular tissues after topical ophthalmic administration. *Lipids*. 2004; 39:469–474. [PubMed: 15506242]
- Tarrago-Trani MT, Phillips KM, Lemar LE, Holden JM. New and existing oils and fats used in products with reduced trans-fatty acid content. *J Am Diet Assoc*. 2006; 106:867–880. [PubMed: 16720128]
- Terasawa Y, Ladha Z, Leonard SW, Morrow JD, Newland D, Sanan D, Packer L, Traber MG, Farese RV Jr. Increased atherosclerosis in hyperlipidemic mice deficient in alpha-tocopherol transfer protein and vitamin E. *Proceedings of the National Academy of Sciences of the United States of America*. 2000; 97:13830–13834. [PubMed: 11095717]
- Theriault A, Chao JT, Gapor A. Tocotrienol is the most effective vitamin E for reducing endothelial expression of adhesion molecules and adhesion to monocytes. *Atherosclerosis*. 2002; 160:21–30. [PubMed: 11755919]
- Theriault A, Wang Q, Gapor A, Adeli K. Effects of gamma-tocotrienol on ApoB synthesis, degradation, and secretion in HepG2 cells. *Arteriosclerosis, Thrombosis & Vascular Biology*. 1999; 19:704–712.
- Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. *Annual Review of Cell & Developmental Biology*. 1997; 13:513–609.
- Tiahou G, Maire B, Dupuy A, Delage M, Vernet MH, Mathieu-Daude JC, Michel F, Sess ED, Cristol JP. Lack of oxidative stress in a selenium deficient area in Ivory Coast Potential nutritional antioxidant role of crude palm oil. *Eur J Nutr*. 2004; 43:367–374. [PubMed: 15490200]
- Tomeo AC, Geller M, Watkins TR, Gapor A, Bierenbaum ML. Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis. *Lipids*. 1995; 30:1179–1183. [PubMed: 8614310]
- Traber MG, Arai H. Molecular mechanisms of vitamin E transport. *Annual Review of Nutrition*. 1999; 19:343–355.
- Traber MG, Burton GW, Hamilton RL. Vitamin E trafficking. *Annals of the New York Academy of Sciences*. 2004; 1031:1–12. [PubMed: 15753129]
- van der Worp HB, Bar PR, Kappelle LJ, de Wildt DJ. Dietary vitamin E levels affect outcome of permanent focal cerebral ischemia in rats. *Stroke*. 1998; 29:1002–1005. discussion 1005-1006. [PubMed: 9596250]

- van Haaften RI, Haenen GR, Evelo CT, Bast A. Tocotrienols inhibit human glutathione S-transferase P1-1. *IUBMB Life*. 2002; 54:81–84. [PubMed: 12440523]
- Venkatesh TV, Karunanandaa B, Free DL, Rottnek JM, Baszis SR, Valentin HE. Identification and characterization of an Arabidopsis homogentisate phytyltransferase paralog. *Planta*. 2006; 223:1134–1144. [PubMed: 16408209]
- Vraka PS, Drouza C, Rikkou MP, Odysseos AD, Keramidias AD. Synthesis and study of the cancer cell growth inhibitory properties of alpha-, gamma-tocopheryl and gamma-tocotrienyl 2-phenylselenyl succinates. *Bioorg Med Chem*. 2006; 14:2684–2696. [PubMed: 16378730]
- Wada S, Satomi Y, Murakoshi M, Noguchi N, Yoshikawa T, Nishino H. Tumor suppressive effects of tocotrienol in vivo and in vitro. *Cancer Lett*. 2005; 229:181–191. [PubMed: 16098658]
- Wagner KH, Kamal-Eldin A, Elmadfa I. Gamma-tocopherol--an underestimated vitamin? *Ann Nutr Metab*. 2004; 48:169–188. [PubMed: 15256801]
- Wan Nazaimoon WM, Khalid BA. Tocotrienols-rich diet decreases advanced glycosylation end-products in non-diabetic rats and improves glycemic control in streptozotocin-induced diabetic rats. *Malays J Pathol*. 2002; 24:77–82. [PubMed: 12887164]
- Watkins T, Lenz P, Gapor A, Struck M, Tomeo A, Bierenbaum M. gamma-Tocotrienol as a hypocholesterolemic and antioxidant agent in rats fed atherogenic diets. *Lipids*. 1993; 28:1113–1118. [PubMed: 8121254]
- Weber SU, Thiele JJ, Han N, Luu C, Valacchi G, Weber S, Packer L. Topical alpha-tocotrienol supplementation inhibits lipid peroxidation but fails to mitigate increased transepidermal water loss after benzoyl peroxide treatment of human skin. *Free Radic Biol Med*. 2003; 34:170–176. [PubMed: 12521598]
- Whittle KJ, Dunphy PJ, Pennock JF. The isolation and properties of delta-tocotrienol from Hevea latex. *Biochemical Journal*. 1966; 100:138–145. [PubMed: 5965249]
- Wie MB, Koh JY, Won MH, Lee JC, Shin TK, Moon CJ, Ha HJ, Park SM, Kim HC. BAPTA/AM, an intracellular calcium chelator, induces delayed necrosis by lipoxygenase-mediated free radicals in mouse cortical cultures. *Prog Neuropsychopharmacol Biol Psychiatry*. 2001; 25:1641–1659. [PubMed: 11642660]
- Yamamoto S. Mammalian lipoxygenases: molecular structures and functions. *Biochimica et Biophysica Acta*. 1992; 1128:117–131. [PubMed: 1420284]
- Yamasaki M, Nishida E, Nou S, Tachibana H, Yamada K. Cytotoxicity of the trans10,cis12 isomer of conjugated linoleic acid on rat hepatoma and its modulation by other fatty acids, tocopherol, and tocotrienol. *In Vitro Cell Dev Biol Anim*. 2005; 41:239–244. [PubMed: 16223339]
- Yamashita K, Ikeda S, Iizuka Y, Ikeda I. Effect of sesaminol on plasma and tissue alpha-tocopherol and alpha-tocotrienol concentrations in rats fed a vitamin E concentrate rich in tocotrienols. *Lipids*. 2002; 37:351–358. [PubMed: 12030315]
- Yano Y, Satoh H, Fukumoto K, Kumadaki I, Ichikawa T, Yamada K, Hagiwara K, Yano T. Induction of cytotoxicity in human lung adenocarcinoma cells by 6-O-carboxypropyl-alpha-tocotrienol, a redox-silent derivative of alpha-tocotrienol. *Int J Cancer*. 2005; 115:839–846. [PubMed: 15723336]
- Yao Y, Clark CM, Trojanowski JQ, Lee VM, Pratico D. Elevation of 12/15 lipoxygenase products in AD and mild cognitive impairment. *Ann Neurol*. 2005; 58:623–626. [PubMed: 16037976]
- Yap SP, Yuen KH, Lim AB. Influence of route of administration on the absorption and disposition of alpha-, gamma- and delta-tocotrienols in rats. *J Pharm Pharmacol*. 2003; 55:53–58. [PubMed: 12625867]
- Yap SP, Yuen KH, Wong JW. Pharmacokinetics and bioavailability of alpha-, gamma- and delta-tocotrienols under different food status. *J Pharm Pharmacol*. 2001; 53:67–71. [PubMed: 11206194]
- Yoneda T, Lowe C, Lee CH, Gutierrez G, Niewolna M, Williams PJ, Izbicka E, Uehara Y, Mundy GR. Herbimycin A, a pp60c-src tyrosine kinase inhibitor, inhibits osteoclastic bone resorption in vitro and hypercalcemia in vivo. *J Clin Invest*. 1993; 91:2791–2795. [PubMed: 8514886]
- Yoshida Y, Itoh N, Hayakawa M, Piga R, Cynshi O, Jishage K, Niki E. Lipid peroxidation induced by carbon tetrachloride and its inhibition by antioxidant as evaluated by an oxidative stress marker, HODE. *Toxicol Appl Pharmacol*. 2005; 208:87–97. [PubMed: 16164964]

- Yoshida Y, Niki E, Noguchi N. Comparative study on the action of tocopherols and tocotrienols as antioxidant: chemical and physical effects. *Chem Phys Lipids*. 2003; 123:63–75. [PubMed: 12637165]
- Yu FL, Gapor A, Bender W. Evidence for the preventive effect of the polyunsaturated phytol side chain in tocotrienols on 17beta-estradiol epoxidation. *Cancer Detect Prev*. 2005; 29:383–388. [PubMed: 16055275]
- Yu SG, Thomas AM, Gapor A, Tan B, Qureshi N, Qureshi AA. Dose-response impact of various tocotrienols on serum lipid parameters in 5-week-old female chickens. *Lipids*. 2006; 41:453–461. [PubMed: 16933790]
- Yu W, Simmons-Menchaca M, Gapor A, Sanders BG, Kline K. Induction of apoptosis in human breast cancer cells by tocopherols and tocotrienols. *Nutrition & Cancer*. 1999; 33:26–32. [PubMed: 10227040]
- Zhou C, Tabb MM, Sadatrafiei A, Grun F, Blumberg B. Tocotrienols activate the steroid and xenobiotic receptor, SXR, and selectively regulate expression of its target genes. *Drug Metab Dispos*. 2004; 32:1075–1082. [PubMed: 15269186]
- Zingg JM, Azzi A. Non-antioxidant activities of vitamin E. *Curr Med Chem*. 2004; 11:1113–1133. [PubMed: 15134510]




Figure 1. Vitamin E: variations and nomenclature

A, R¹ = R² = R³ = Me, known as α -tocopherol, is designated α -tocopherol or 5,7,8-trimethyltolcol; R¹ = R³ = Me; R² = H, known as, β -tocopherol, is designated, β -tocopherol or 5,8-dimethyltolcol; R¹ = H; R² = R³ = Me, known as γ -tocopherol, is designated γ -tocopherol or 7,8-dimethyltolcol; R¹ = R² = H; R³ = Me, known as δ -tocopherol, is designated δ -tocopherol or 8-methyltolcol. B, R¹ = R² = R³ = H, 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)chroman-6-ol, is designated tocotrienol; R¹ = R² = R³ = Me, formerly known as ζ 1 or ζ 2-tocopherol, is designated 5,7,8-trimethyltocotrienol or α -tocotrienol. The name tocochromanol-3 has also been used; R¹ = R³ = Me; R² = H, formerly known as ϵ -tocopherol, is designated 5,8-dimethyltocotrienol or β -tocotrienol; R¹ = H; R² = R³ = Me, formerly known as η -tocopherol, is designated 7,8-dimethyltocotrienol or γ -tocotrienol. The name plastochromanol-3 has also been used; R¹ = R² = H; R³ = Me is designated 8-methyltocotrienol or δ -tocotrienol.




Figure 2. Trends in tocotrienol research and in vitamin E research as a whole
 Publication data are based on PubMed entries. **A**, comparison of volume of all vitamin E (diamond) research and tocotrienol research (square); **B**, time-dependent changes in the volume of vitamin E research as a whole; **C**, time-dependent changes in the volume of tocotrienol research; **D**, tocotrienol (TCT) publications as a percent of total vitamin E publications reported; **E**, percent increase in tocotrienol publications and that of vitamin E as a whole over time; **F**, trends in NIH funding for tocotrienol research and for vitamin E research as a whole. Based on hits in the Computer Retrieval of Information on Scientific Projects (CRISP) database.

Table 1

TOCOTRIENOLS: THE EMERGENT FACE OF NATURAL VITAMIN E

Neuroprotective	Mouse: At nM concentrations α -tocotrienol, in contrast with α -tocopherol, protects against glutamate-induced neuronal death by suppressing inducible pp60 c-src kinase activation. α -Tocotrienol provided the most potent neuroprotection among all vitamin E analogs. Reported effects of tocotrienol independent of antioxidant property (Sen <i>et al.</i> , 2000)	2000
	Rat: Oral tocotrienol crosses the blood-brain barrier to reach brain tissue; more so for fetal brain while pregnant mother is supplemented with tocotrienol (Roy <i>et al.</i> , 2002)	2002
	Mouse: At nM concentrations α -tocotrienol, in contrast with α -tocopherol, protects against glutamate-induced neuronal death by suppressing inducible 12-lipoxygenase activation (Khanna <i>et al.</i> , 2003). 12-Lipoxygenase deficient mice are protected against stroke (Khanna <i>et al.</i> , 2005b).	2003
	Mouse: Injected α -tocotrienol decreased the size of the cerebral infarcts 1 day after stroke; γ -tocotrienol and delta-tocotrienol did not protect (Mishima <i>et al.</i> , 2003)	2003
	Human: Tocotrienols induced IKBKAP expression: a possible therapy for familial dysautonomia (Anderson <i>et al.</i> , 2003)	2003
	Rat: α -Tocotrienol provided the most potent neuroprotection among vitamin E analogs on cultured striatal neurons (Osakada <i>et al.</i> , 2004)	2004
	Human: Administration of tocotrienol to individuals with familial dysautonomia resulted in beneficial changes in their peripheral blood cells (Anderson and Rubin 2005)	2005
	Rat: Attomole quantity of α -tocotrienol, not α -tocopherol, microinjected to primary neurons protects against glutamate cytotoxicity (Khanna <i>et al.</i> , 2005b)	2005
	SHR: α -Tocotrienol protects against stroke in vivo (Khanna <i>et al.</i> , 2005b)	2005
	Rat: α -Tocopherol and γ -tocotrienol have comparable protective effects on H_2O_2 -induced death of astrocytes (Mazlan <i>et al.</i> , 2006)	2006
	Rat: At nM concentration, α -tocotrienol protects neurons. Vitamin E analogs play an essential role in neuronal maintenance and survival in the CNS (Numakawa <i>et al.</i> , 2006)	2006
	Mouse: The neuroprotective property of α -tocotrienol is antioxidant-independent at nM but antioxidant-dependent at μ M concentrations (Khanna <i>et al.</i> , 2006)	2006
	Mouse: At nM concentration α -tocotrienol protects against homocysteic acid induced neurotoxicity (Khanna <i>et al.</i> , 2006)	2006
Chicken: Three double bonds in the isoprenoid chain essential for the inhibition of cholesterogenesis; tocopherols do not share this property (Qureshi <i>et al.</i> , 1986)	1986	
Human: Lowered serum cholesterol in hypercholesterolemics (Qureshi <i>et al.</i> , 1991b); lowered both serum total cholesterol (TC) and low-density-lipoprotein cholesterol (Tan <i>et al.</i> , 1991)	1991	
Hypocholesterolemic		

	Pigs: Reduced plasma cholesterol, apolipoprotein B, thromboxane B ₂ , and platelet factor 4 in pigs with inherited hyperlipidemias (Qureshi <i>et al.</i> , 1991a)	1992
	In vitro: Post-transcriptional suppression of HMG-CoA reductase by a process distinct from other known inhibitors of cholesterol biosynthesis (Pearce <i>et al.</i> , 1992)	1992
	Regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (Parker <i>et al.</i> , 1993)	1993
	HepG2: The farnesyl side chain and the methyl/hydroxy substitution pattern of gamma-tocotrienol responsible for HMG CoA reductase suppression (Pearce <i>et al.</i> , 1994)	1994
	isoprenoid-mediated suppression of mevalonate synthesis depletes tumor tissues of two intermediate products, farnesyl pyrophosphate and geranylgeranyl pyrophosphate, which are incorporated post-translationally into growth control-associated proteins (Elson and Qureshi 1995)	1995
	Human: Lowered plasma cholesterol level in hypercholesterolemic subjects (Qureshi <i>et al.</i> , 1995)	1995
	Chicken: The effects of a tocotrienol/lovastatin combination were no greater than that of tocotrienol alone, indicating that tocotrienol produced a maximum cholesterol lowering effect (Qureshi and Peterson 2001)	2001
	Swine: Tocotrienols suppress cholesterol synthesis in hereditary hypercholesterolemic swine (Qureshi <i>et al.</i> , 2001a)	2001
	Human: Tocotrienol, not tocopherol, hypocholesterolemic in humans; claimed that tocotrienol is converted to tocopherol in vivo (Qureshi <i>et al.</i> , 2001c)	2001
	Human: Dose-dependent suppression of serum cholesterol by tocotrienol-rich fraction of rice bran in hypercholesterolemic humans (Qureshi <i>et al.</i> , 2002)	2002
	Hamster: Tocotrienols lower total cholesterol and low density lipoprotein plasma levels (Raederstorff <i>et al.</i> , 2002)	2002
	Rat: Suppression of hypercholesterolaemia in rats by tocotrienol-rich fraction isolated from rice bran oil (Iqbal <i>et al.</i> , 2003)	2003
	Rat: TRF lowered HMG-CoA reductase activity in hyperlipidemics (Minhajuddin <i>et al.</i> , 2005)	2005
	Rat: Tocotrienol-rich rice bran oil-containing diet can significantly suppress hyperlipidemic and hyperinsulinemic responses in diabetics (Chen and Cheng 2006)	2006
	δ- and γ-tocotrienol, but not other forms of vitamin E, cause HMG Co-A reductase ubiquitination and degradation. Results explain hypercholesterolemic effects of tocotrienol noted in humans and animals (Song and Debose-Boyd 2006).	2006
ApoB level reduction in hypercholesterolemic subjects	Human: in HepG2 cells tocotrienol (not tocopherol) stimulates apoB degradation possibly as the result of decreased apoB translocation into the endoplasmic reticulum lumen (Theriault <i>et al.</i> , 1999)	1999
Anti-hypertensive	Rat: Depressed (better than α-tocopherol) age-related increase in the systolic blood pressure of spontaneously hypertensive rats (Koba <i>et al.</i> , 1992)	1992

Hypocholesterolemic and antioxidant	Rat: spares plasma tocopherol (Watkins <i>et al.</i> , 1993)	1993
Lowering blood pressure; antioxidant	SHR: Supplement of γ -tocotrienol may prevent increased blood pressure, reduce lipid peroxides in plasma and blood vessels and enhanced total antioxidant status (Newaz and Nawal 1999)	1999
Cardioprotective	Rat: TRF protected against ischemia-reperfusion in isolated heart by c-Src inhibition (Das <i>et al.</i> , 2005)	2005
Antioxidant	In vitro: Better than α -tocopherol (Serbinova <i>et al.</i> , 1991)	1991
	In vitro: Facilitates antioxidant recycling (Kagan <i>et al.</i> , 1992)	1992
	In vitro: Tocotrienol is better than tocopherol; tocotrienol is located closer to the cell membrane surface (Suzuki <i>et al.</i> , 1993)	1993
	Human: Dietary tocotrienols become incorporated into circulating human lipoproteins where they react with peroxyl radicals as efficiently as the corresponding tocopherol isomers (Suama <i>et al.</i> , 1993)	1993
	Rat: Protects brain against oxidative damage (Kamat and Devasagayam 1995)	1995
	Human: Controls the course of carotid atherosclerosis (Tomeo <i>et al.</i> , 1995)	1995
	Human: α -Tocotrienol is more potent than α -tocopherol in protecting against free radical-induced impairment of erythrocyte deformability (Begum and Terao 2002)	2002
	Rat: Comparable effects of a tocotrienol-rich fraction and tocopherol in aspirin-induced lipid peroxidation mediated gastric lesions (Nafeeza <i>et al.</i> , 2002)	2002
	Rat: Antioxidant effects of γ -tocotrienol in spontaneously hypertensive rats (Newaz <i>et al.</i> , 2003)	2003
	Tocopherols and tocotrienols have comparable antioxidant properties; Some of the vitamin E formulations tested showed antioxidant activities superior to d-alpha-tocopherol (Naguib <i>et al.</i> , 2003)	2003
	The corresponding tocopherols and tocotrienols exert comparable antioxidant activity; tocotrienols are more readily transferred between the membranes and incorporated into the membranes than tocopherols (Yoshida <i>et al.</i> , 2003)	2003
	Human: Topical α -tocotrienol supplementation inhibits lipid peroxidation in human skin (Weber <i>et al.</i> , 2003)	2003
	Human: Lack of oxidative stress in a selenium deficient area in Ivory Coast Potential nutritional antioxidant role of crude palm oil (Tiahou <i>et al.</i> , 2004)	2004
Rat: Palm oil tocotrienol mixture better than α -tocopherol acetate in protecting bones against free-radical induced elevation of bone-resorbing cytokines (Soelaiman <i>et al.</i> , 2004)	2004	
Mouse: Rice-trienol exerted a protective effect against oxidative damage in diabetes mellitus (Kanaya <i>et al.</i> , 2004)	2004	
Antioxidant property of tocots: $\alpha > \beta = \gamma > \delta$; not influenced by the nature of the isoprenoid tail (Somnen <i>et al.</i> , 2005)	2005	

	α -Tocotrienol and α -tocopherol have comparable antioxidant efficacy (Yamasaki <i>et al.</i> , 2005)	2005
	Mouse: Both γ -tocopherol as well as γ -tocotrienol has antioxidant properties <i>in vivo</i> (Yoshida <i>et al.</i> , 2005)	2005
	Polyunsaturated isoprenoid side chain in tocotrienols have antioxidant properties (Yu <i>et al.</i> , 2005)	2006
	Individual tocotrienols display different antioxidant potencies: $\delta > \gamma > \alpha$ (Palozza <i>et al.</i> , 2006)	2006
	γ -tocotrienol > α -tocotrienol > α -tocopherol as antioxidant. Tocotrienol regenerated oxidized carotenes demonstrating synergistic action (Schroeder <i>et al.</i> , 2006).	2006
Antiaging/antioxidant	C. elegans: Tocotrienol, not tocopherol, administration reduced the accumulation of protein carbonyl and consequently extended the mean life span but not the maximum life span (Adachi and Ishii 2000; Collins <i>et al.</i> , 2006).	2000
Anti-cancer	Mouse: Intraperitoneally injected tocotrienol prevented transplanted tumors (Komiya <i>et al.</i> , 1989)	1989
	Rat: Tocotrienol-rich palm oil prevented chemically-induced mammary tumorigenesis (Sundram <i>et al.</i> , 1989)	1989
	Rat: Tocotrienol, but not tocopherol, increased tumor latency in mammary tumor model (Gould <i>et al.</i> , 1991)	1991
	Rat: Tocotrienol. chemopreventive in hepatic tumor model (Nghah <i>et al.</i> , 1991)	1991
	Rat: Tocotrienol. chemopreventive in hepatic tumor model (Rahmat <i>et al.</i> , 1993)	1993
	Human: Suppresses activation of Epstein-Barr virus early antigen expression in PMA-activated lymphoblastoid Raji cells (Goh <i>et al.</i> , 1994)	1994
	Human: Tocotrienol, not tocopherol, suppresses growth of a human breast cancer cell line in culture (Nesaretnam <i>et al.</i> , 1995)	1995
	Human: Inhibited proliferation of estrogen receptor-negative MDA-MB-435 and -positive MCF-7 breast cancer cells (Guthrie <i>et al.</i> , 1997)	1997
	Mouse: Isoprenoids suppress the growth of murine B16 melanomas <i>in vitro</i> and <i>in vivo</i> (He <i>et al.</i> , 1997)	1997
	Human: Inhibit the growth of human breast cancer cells irrespective of estrogen receptor status (Nesaretnam <i>et al.</i> , 1998)	1998
	Human: Apoptosis and cell-cycle arrest in human and murine tumor cells are initiated by isoprenoids (Mo and Elson 1999)	1999
	Human: Naturally occurring tocotrienols and RRR- δ -tocopherol are effective apoptotic inducers for human breast cancer cells (Yu <i>et al.</i> , 1999)	1999
	Human: Tocotrienols inhibit growth of ZR-75-1 breast cancer cells (Nesaretnam <i>et al.</i> , 2000)	2000
	Mouse: Highly potent γ - and δ -tocotrienol isoforms may play a physiological role in modulating normal mammary gland growth, function, and remodeling (McIntyre <i>et al.</i> , 2000b)	2000

2000	Mouse: highly malignant breast cancer cells were the most sensitive, whereas the preneoplastic cells were the least sensitive to the antiproliferative and apoptotic effects of tocotrienols (McIntyre <i>et al.</i> , 2000a)
2001	Mouse: Tocotrienols are significantly more potent than tocopherols in suppressing EGF-dependent normal mammary epithelial cell growth. The inhibitory effects of specific tocopherol and tocotrienol isoforms on EGF-dependent normal mammary epithelial cell mitogenesis occurs downstream from the EGF-receptor and appears to be mediated, at least in part, by a reduction in PKC α activation (Sylvester <i>et al.</i> , 2001)
2002	Mouse: Antiproliferative effects of tocotrienols in preneoplastic mammary epithelial cells do not reflect a reduction in EGF-receptor mitogenic responsiveness, but rather, result from an inhibition in early post-receptor events involved in cAMP production upstream from EGF-dependent MAPK and phosphoinositide 3-kinase/Akt mitogenic signaling (Sylvester <i>et al.</i> , 2002)
2003	Rat: Suppression of 7,12-dimethylbenz[<i>a</i>]anthracene-induced carcinogenesis by tocotrienol-rich fraction isolated from rice bran oil (Iqbal <i>et al.</i> , 2003)
2003	Mouse: Tocotrienol-induced apoptosis in mammary cancer cells is mediated through activation of the caspase-8 signaling pathway and is independent of caspase-9 activation (Shah <i>et al.</i> , 2003)
2004	Mouse: Tocotrienol-induces caspase-8 activation, unrelated to death receptor apoptotic signaling, in neoplastic mammary epithelial cells (Shah and Sylvester 2004)
2004	Rat: Tocotrienol induces apoptosis in dRLH-84 hepatoma cells (Sakai <i>et al.</i> , 2004)
2004	Rat: Tocotrienol-rich fraction isolated from rice bran oil suppressed diethylnitrosamine and 2-acetylaminofluorene-induced hepatocarcinogenesis (Iqbal <i>et al.</i> , 2004)
2004	Human: Tocotrienol disrupts mitochondrial function and causes apoptosis of breast cancer cells (Takahashi and Loo 2004)
2004	Human: Pro-apoptotic properties of δ -tocotrienol in breast cancer cells (Shun <i>et al.</i> , 2004)
2004	Human: Supplementation of tocotrienol rich fraction of palm oil significantly and specifically affected MCF-7 cell response after tumor formation <i>in vivo</i> by an antioxidant-independent mechanism (Nesaretnam <i>et al.</i> , 2004)
2004	Human: Tocotrienol-rich fraction of palm oil activated p53, modulated Bax/Bcl2 ratio and induced apoptosis independent of cell cycle association in colorectal cancer RKO cells (Agarwal <i>et al.</i> , 2004)
2005	Mouse: Tocotrienol kills liver cancer cells (Har and Keong 2005)
2005	Human: γ -Tocotrienol induces apoptosis of hepatoma Hep3B cells (Sakai <i>et al.</i> , 2005).
2005	Human: a redox-silent analogue of α -tocotrienol, 6-O-carboxypropyl- α -tocotrienol, possess anticancer effects against lung adenocarcinoma showing poor prognosis based on the mutation of ras genes (Yano <i>et al.</i> , 2005)
2005	Mouse: γ -Tocotrienol is anti-neoplastic in mammary epithelial cells (Shah and Sylvester 2005a; Shah and Sylvester 2005b; Sylvester and Shah 2005a; Sylvester and Shah 2005b; Sylvester <i>et al.</i> , 2005)
2005	Mouse: Tocotrienols have anti-cancer properties <i>in vitro</i> and <i>in vivo</i> (Wada <i>et al.</i> , 2005)

	Isoprenoid side chain of tocotrienol, not found in tocopherols, may prevent E2 epoxide induced breast cancer carcinogenesis at the initiation (Yu <i>et al.</i> , 2005)	2005
	Mouse: Preferential radiation sensitization of prostate cancer by γ -tocotrienol(Kumar <i>et al.</i> , 2006)	2006
	Tocotrienols targeted both ρ l lambda and angiogenesis as anti-cancer agents.(Mizushima <i>et al.</i> , 2006)	2006
	Human: TRF of palm oil inhibited cellular proliferation and accelerated apoptosis (Srivastava and Gupta 2006).	2006
	Human: The vitamin E succinate selenium-conjugated γ -tocotrienyl-2-phenylselenyl succinate decreased prostate cancer cell viability by stimulating caspase 3 dependent apoptosis (Vraka <i>et al.</i> , 2006)	2006
	Human: In contrast to tocopherols, tocotrienol potently inhibited telomerase activity in colorectal adenocarcinoma cells (Eitsuka <i>et al.</i> , 2006)	2006
Modulating normal mammary gland growth, function, and remodeling	Mouse: Mammary epithelial cells more easily or preferentially took up tocotrienols as compared to tocopherols (McIntyre <i>et al.</i> , 2000b)	2000
Antiangiogenic	Bovine: Tocotrienol, but not tocopherol, inhibited both the proliferation and tube formation of aortic endothelial cells (Inokuchi <i>et al.</i> , 2003)	2003
	Human/Chicken: Tocotrienol, not tocopherol, inhibited angiogenesis and telomerase activity (Nakagawa <i>et al.</i> , 2004)	2004
	Bovine: Tocotrienol, not tocopherol, limited angiogenic responses <i>in vitro</i> (Miyazawa <i>et al.</i> , 2004)	2004
	Bovine: Tocotrienols inhibited the proliferation of and formation of tubes by aortic endothelial cells, with δ -tocotrienol having the greatest effect. Tocotrienols targeted both ρ l lambda and angiogenesis as anti-cancer agents (Mizushima <i>et al.</i> , 2006).	2006
Antiproliferative and apoptotic	Mouse: Preneoplastic and neoplastic mammary epithelial cells α - and γ -tocopherol had no effect on cell proliferation (McIntyre <i>et al.</i> , 2000a)	2000
	Cancer cell lines: Not α -tocotrienol but γ -tocotrienol was apoptogenic, and more so when succinylated. Shortening the aliphatic side chain of gamma-tocotrienol by one isoprenyl unit increased its activity (Birringer <i>et al.</i> , 2003)	2003
Hypocholesterolemic, antioxidant & antitumor	Chicken: The number and position of methyl substituents in tocotrienols affect their hypocholesterolemic, antioxidant, and antitumor properties; tocotrienol better than α - tocopherol (Qureshi <i>et al.</i> , 2000)	2000
Anti-atherogenic	Mouse: Palm tocotrienols protect ApoE +/- mice from diet-induced atheroma formation (Black <i>et al.</i> , 2000)	2001
	Mouse: Tocotrienols inhibit atherosclerotic lesions in ApoE-deficient mice (Qureshi <i>et al.</i> , 2001b)	2001
	Rat: TRF supplementation decreased the lipid parameters in a dose-dependent manner in rats fed atherogenic diet (Minhajuddin <i>et al.</i> , 2005)	2005
	Human: daily intake of dietary TRF by type 2 diabetes was beneficial against atherogenesis (Baliarsingh <i>et al.</i> , 2005)	2005
Serum lipoproteins; platelet function	Human: in men at risk for cardiovascular disease tocotrienol supplements used had no marked favorable effects (Mensink <i>et al.</i> , 1999)	1999

Anti-inflammatory	Human: Tocotrienols inhibit monocyte-endothelial cell adhesion (Chao <i>et al.</i> , 2002)	2002
	Human: Tocotrienol is the most effective vitamin E for reducing endothelial expression of adhesion molecules and adhesion to monocytes (Theriault <i>et al.</i> , 2002)	2002
	Human: The efficacy of tocotrienol for reduction of VCAM-1 expression and adhesion of THP-1 cells to HUVECs was 10-fold higher than that of tocopherol (Noguchi <i>et al.</i> , 2003)	2003
	Human: Compared to α -tocopherol, tocotrienols more potent displayed a more profound inhibitory effect on adhesion molecule expression and monocytic cell adherence (Naito <i>et al.</i> , 2005).	2005
	Human: α -Tocotrienol, not tocopherol, restricted proliferation of human Tenon's capsule fibroblast (Meyenberg <i>et al.</i> , 2005)	2005
Hypolipidemic	Rat: Serum triglycerides lower in tocotrienol fed; higher IgM productivity of spleen lymphocytes and IgA, IgG, and higher IgM productivity mesenteric lymph node lymphocytes (Kaku <i>et al.</i> , 1999)	1999
	Human: daily intake of dietary TRF by type 2 diabetics was beneficial against hyperlipidemia (Baliarsingh <i>et al.</i> , 2005)	2005
Immune function	Rats: Feeding affects proliferation and function of spleen and mesenteric lymph node lymphocytes (Gu <i>et al.</i> , 1999)	1999
	Rat: preferential absorption of α -tocotrienol compared to γ - and δ -tocotrienols and α -tocopherol (Ikeda <i>et al.</i> , 1996)	1996
Drug metabolism	Tocotrienols inhibit human glutathione S-transferase P1-1 (van Haafden <i>et al.</i> , 2002)	2002
	Human: Vitamin E are able to activate gene expression via the pregnane X receptor (PXR), a nuclear receptor regulating a variety of drug metabolizing enzymes. Tocotrienols more potent than tocopherols (Landes <i>et al.</i> , 2003)	2003
Eye	Human: Tocotrienols, not tocopherols, activate the steroid and xenobiotic receptor (SXR) and selectively regulate expression of its target genes (Zhou <i>et al.</i> , 2004)	2004
	Mouse: Tocopherol, but not tocotrienol, may induce CYP3A11 and interfere with drug metabolism (Kluth <i>et al.</i> , 2005)	2005
Bone	Rat: Preferential uptake of topically applied tocotrienol, over tocopherol, by ocular tissues (Tamito <i>et al.</i> , 2004)	2004
	Rat: Tocotrienols are needed for normal bone calcification in growing female rats (Norazlina <i>et al.</i> , 2002)	2002
Obesity & Osteoporosis	Rat: Tocotrienol offers better protection than tocopherol from free radical-induced damage of bone (Ahmad <i>et al.</i> , 2005)	2005
	Rat: Tocotrienol, not tocopherol, has the potential to be utilized as a prophylactic agent in preventing side effects of long-term glucocorticoid use (Ima-Nirwana and Suhaimiza 2004)	2004
Diabetes	Rat: Tocotrienols-rich diet decreased advanced glycosylation end-products in non-diabetic rats and improved glyceemic control in streptozotocin-induced diabetic rats (Wan Nazaimoon and Khalid 2002)	2002
	Rat: Tocopherol, not alone, but in combination with tocotrienol and ubiquinone decreased gastric lesion (Nafeeza and Kang 2005)	2005

	Rat: Tocotrienol, not tocopherol, prevents stress-induced adverse changes in the gastric acidity and gastrin level (Azlima <i>et al.</i> , 2005)	2005
Natriuretic function	Rat: An oral administration of γ -tocotrienol increases plasma concentration of 2,7,8-trimethyl-2-(beta-carboxyethyl)-6-hydroxy chroman (LLU-alpha, gamma-CEHC), a natriuretic compound (Hattori <i>et al.</i> , 2000)	2000
	Rat: γ -Tocotrienol is a natriuretic hormone precursor (Saito <i>et al.</i> , 2003)	2003
Bioavailability	Mouse: Supplemented tocotrienol not detected in the brain (Podda <i>et al.</i> , 1996). See 2002* below.	1996
	Human: Following supplementation, $\sim 1\mu\text{M}$ tocotrienol detected in human plasma (O'Byrne <i>et al.</i> , 2000)	2000
	Rat: The skin is a unique tissue in respect to its ability to discriminate between various vitamin E analogs; it preferentially uptakes dietary tocotrienols (Ikeda <i>et al.</i> , 2000)	2000
	Human: Increased absorption of the tocotrienols in the fed versus fasted state; $\sim 1\mu\text{M}$ tocotrienol detected in human plasma (Yap <i>et al.</i> , 2001)	2001
	Human: Tocotrienols, like tocopherols, are metabolized to CEHC; however, the quantities excreted in human urine are small in relation to dose size (Lodge <i>et al.</i> , 2001)	2001
	Rat: Dietary sesame seeds elevate the tissue concentrations of orally taken tocopherols and tocotrienols (Ikeda <i>et al.</i> , 2001)	2001
	Rat: Oral tocotrienol crosses the blood-brain barrier to reach brain tissue; more so for fetal brain while pregnant mother is supplemented with tocotrienol (Roy <i>et al.</i> , 2002)	2002*
	Human: In HepG2 cells, tocotrienols are metabolized essentially like tocopherols, i.e., by ω -oxidation followed by β -oxidation of the side chain. Quantitatively, tocotrienols are degraded to a larger extent than tocopherols (Burringer <i>et al.</i> , 2002)	2002
	Rat: Sesame lignans added to diet increased plasma and tissue concentrations of supplemented tocotrienols (Yamashita <i>et al.</i> , 2002)	2002
	Rat: In epididymal adipose, renal adipose, subcutaneous adipose and brown adipose tissues and in the heart, the tocotrienol levels were maintained or increased for 24 h after intragastric administration. In the serum, liver, mesenteric lymph node, spleen and lungs, the tocotrienol levels were highest 8 h after the administration (Okabe <i>et al.</i> , 2002)	2002
	Human: novel formulation of tocotrienol developed to improve bioavailability in humans (Ho <i>et al.</i> , 2003)	2003
	Rat: Dietary α -tocopherol decreases α -tocotrienol but not γ -tocotrienol concentration in rats (Ikeda <i>et al.</i> , 2003)	2003
	Tocotrienols are more readily transferred between the membranes and incorporated into the membranes than tocopherols (Yoshida <i>et al.</i> , 2003)	2003
	Human: α -Tocotrienol accumulate in endothelial cells to levels approximately 10-fold greater than that of α -tocopherol (Noguchi <i>et al.</i> , 2003)	2003
	Rat: Of the three tocotrienols, α -tocotrienol had the highest oral bioavailability, at about 27.7+/-9.2%, compared with γ - and δ -tocotrienols, which had values of 9.1+/-2.4% and 8.5+/-3.5%, respectively. Tocotrienols were found to be negligibly absorbed when administered intraperitoneally and intramuscularly (Yap <i>et al.</i> , 2003)	2003

<p>Human: The $t_{1/2}$ of tocotrienols is short, ranging from 3.8–4.4 h for γ- and α-tocotrienol (Schwedhelm <i>et al.</i>, 2003)</p>	<p>2003</p>
<p>Human: Following the intervention with palm vitamin E, tocotrienols are detected in total blood plasma, TRP, LDL and HDL. Tocotrienols appeared in the blood stream at 2h interval & disappeared within 24 h. Tocotrienols concentration in total plasma plasma, TRP & LDL peaked between 4 to 6 h; in HDL, tocotrienol concentrations peaked at 8 h after supplementation. α-tocopherol was the major vitamin E detected in plasma. Tocotrienols have a very short duration of absorption & distribution in circulating blood (Fairus <i>et al.</i>, 2004).</p>	<p>2004</p>
<p>Rat: Following topical application of small amounts, the concentration of α-tocotrienol increased markedly in ocular tissues (e.g. crystalline lens, neural retina, and eye cup); however, no significant increase was observed in the case of α-tocopherol (Tanito <i>et al.</i>, 2004)</p>	<p>2004</p>
<p>Human: Tocotrienol uptake by aortic endothelial cells approximately 25-95-fold greater than that of α-tocopherol (Naito <i>et al.</i>, 2005).</p>	<p>2005</p>
<p>Rat: Orally taken tocotrienol reaches all vital organs in vivo (Khanna <i>et al.</i>, 2005a)</p>	<p>2005</p>
<p>Mouse: Orally fed tocotrienol can be delivered to vital organs in vivo even in TTP-deficient mice (Khanna <i>et al.</i>, 2005a). There are mechanisms other than TTP to transport tocotrienol to tissues.</p>	<p>2005</p>
<p>Chicken: Estimated that the safe dose of various tocotrienols for human consumption might be 200-1000 mg/d (Yu <i>et al.</i>, 2006)</p>	<p>2006</p>
<p>Human: Single dose of tocotrienol supplementation results in 3μM peak plasma concentration; 1.7 μM in LDL, 0.9 μM in triglyceride-rich lipoprotein, and 0.5 μM in HDL. The peak plasma level corresponds to 12- to 30-fold more than the concentration of α-tocotrienol required to completely prevent neurodegeneration. Tocotrienols were detected in the blood plasma and all lipoprotein sub-fractions studied postprandial (Khosla <i>et al.</i>, 2006)</p>	<p>2006</p>

CEHC, carboxyethyl-hydroxychromans; EGF, epidermal growth factor; HDL, high density lipoprotein; HMG CoA reductase, 3-hydroxy-3-methylglutaryl coenzyme A reductase; HUVEC, human umbilical vein (derived) endothelial cells; IKBKAP, gene encoding IkbkappaB kinase complex-associated protein; LDL, low density lipoprotein; SHR, spontaneously hypertensive rats; TRF, tocotrienol-rich fraction; TRP, triglyceride rich particles, TTP, tocopherol-transport protein.